

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 14:31:01 ; Search time 40 seconds
(without alignments)
38.467 Million cell updates/sec

Title: US-09-763-848-1
Perfect score: 99
Sequence: 1 PEWPSYLGVEKLGPPY 16
Scoring table: BLOSOM62
Gapop 10.0 , Gapext 0.5

Searched: 283308 seqs, 96168682 residues

Total number of hits satisfying chosen parameters: 283308

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_76:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	99	100.0	284	2 S68216	phosphoprotein pho
2	52	52.5	406	2 S42394	G-box-binding prot
3	52	52.5	700	2 S38361	calpain (EC 3.4.22
4	51	51.5	349	2 A41349	histone-specific t
5	51	51.5	349	2 S77570	transcription fact
6	51	51.5	700	1 C1H0H2	calpain (EC 3.4.22
7	49	49.5	705	1 C1CHH	calpain (EC 3.4.22
8	49	49.5	842	2 T23715	hypothetical prote
9	49	49.5	1160	2 T23713	hypothetical prote
10	49	49.5	1286	2 T23714	hypothetical prote
11	48	48.5	127	2 B31807	Ig heavy chain v r
12	48	48.5	601	2 H90159	hypothetical prote
13	47.5	48.0	273	2 D71221	probable morphine
14	47	47.5	245	2 AG0701	Orf 245 protein [i
15	47	47.5	301	1 A48041	protein kinase (EC
16	47	47.5	456	2 T49997	hypothetical prote
17	47	47.5	566	2 T03855	hypothetical prote
18	47	47.5	703	2 A48764	calpain (EC 3.4.22
19	46	46.5	327	2 D83320	hypothetical prote
20	46	46.5	340	1 C64096	aldose 1-epimerase
21	45	45.5	344	2 T00110	integral membrane
22	45	45.5	385	2 T09880	omega-6 desaturase
23	45	45.5	611	1 FPKT	alpha-fetoprotein
24	45	45.5	177	2 S57194	calpain (EC 3.4.22
25	44.5	44.9	177	2 B72580	hypothetical prote
26	44.5	44.9	421	2 AC1481	conserved hypotet
27	44.5	44.9	421	2 AW1120	B. subtilis ywbN p
28	44	44.4	268	2 S08229	chlorophyll a/b-b1
29	44	44.4	401	2 T52250	probable alanine-g

30	44	44.4	554	2 AE0584	asparagine synthet
31	44	44.4	761	2 A53414	A-kinase anchor pr
32	43.5	43.9	359	2 F82316	probable extracell
33	43	43.4	120	2 S22958	adenosylhomocyste
34	43	43.4	267	2 T15645	hypothetical prote
35	43	43.4	378	1 QBY333	ox13 intron 3 prot
36	43	43.4	415	2 S78646	DNA endonuclease I
37	43	43.4	421	2 S33998	K421R protein - Af
38	43	43.4	503	2 C86250	hypothetical prote
39	43	43.4	544	2 T27444	prolyl oligopeptid
40	43	43.4	730	2 D87365	hypothetical prote
41	43	43.4	1094	2 T05472	hypothetical prote
42	43	43.4	1296	2 I40645	botulinum neurotox
43	43	43.4	2970	2 T08839	polyprotein - marm
44	42.5	42.9	401	2 A82221	extracellular solu
45	42.5	42.9	735	2 S58551	photosystem I prot

ALIGNMENTS

RESULT 1

S68216
phosphoprotein phosphatase (EC 3.1.3.16) 1 glycogen-binding chain - rat
N;Alternate names: 33K protein glycogen-binding chain (G(L))
C;Species: Rattus norvegicus (Norway rat)
C;Date: 15-Feb-1997 #sequence_revision 13-Mar-1997 #text_change 17-Mar-1999
C;Accession: S68216; S74276; S68723
R;Doherty, M.J.; Moorhead, G.; Morrice, N.; Cohen, P.; Cohen, P.T.W.
PERS Lett. 375, 294-298, 1995
A;Title: Amino acid sequence and expression of the hepatic glycogen-binding (G(L))-:
A;Reference number: S68216; MUID:96085228; PMID:7498521
A;Accession: S68216
A;Molecule type: mRNA
A;Residues: 1-284 <DOH>
A;Cross-references: GB:S80360; NID:gl245930; PID:gl245931
A;Accession: S74276
A;Molecule type: protein
A;Residues: 21-24;43-56;61-98;150-157;161-169;181-199;201-220;238-253;280-284 <DOE>
R;Moorhead, G.; MacKintosh, C.; Morrice, N.; Cohen, P.
PERS Lett. 362, 101-105, 1995
A;Title: Purification of the hepatic glycogen-associated form of protein phosphatas:
A;Reference number: S68721; MUID:95237359; PMID:7720853
A;Accession: S68723
A;Molecule type: protein
A;Residues: 61-76;150-157 <MOO>
A;Experimental source: liver
C;Keywords: glycogen metabolism; phosphoric monoester hydrolase
F;1-284/Product: phosphoprotein phosphatase 1 glycogen-binding chain #status experi

Query Match 100.0%; Score 99; DB 2; Length 284;
Best Local Similarity 100.0%; Pred. No. 1.1e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGPPY 16
|||||
DB 269 PEWPSYLGVEKLGPPY 284

RESULT 2

S42394
G-box-binding protein - tomato
C;Species: Lycopersicon esculentum (tomato)
C;Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 21-Jul-2000
C;Accession: S42394
R;Meier, I.; Gruissem, W.
Nucleic Acids Res. 22, 470-478, 1994
A;Title: Novel conserved sequence motifs in plant G-box binding proteins and implic:
A;Reference number: S42392; MUID:94173701; PMID:8127687
A;Accession: S42394
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-406 <MEI>

A:Cross-references: EMBL:X74943; NID:g456754; PIDN:CAA52897.1; PID:g456755
 C:Superfamily: fava bean G-box-binding protein; fos/jun DNA-binding domain homology
 F:286-326/Domain: fos/jun DNA-binding domain homology <FJD>

Query Match 52.5%; Score 52; DB 2; Length 406;

Best Local Similarity 46.7%; Pred. No. 2.6;

Matches 7; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15

||||| : || : || :

Db 25 PEWPGQGYFAMPPH 39

RESULT 3

S38361 calpain (EC 3.4.22.17) II large chain - rat

N:Alternate names: calpain II 80K chain

C:Species: Rattus norvegicus (Norway rat)

C>Date: 31-Dec-1993 #sequence_revision 02-Aug-1994 #text_change 22-Jun-1999

C:Accession: S38361; S08650; S39751

R:DeLuca, C.I.; Davies, P.L.; Samis, J.A.; Elce, J.S.

Biochim. Biophys. Acta 1216, 81-93, 1993

A:Title: Molecular cloning and bacterial expression of cDNA for rat calpain II 80 kDa su

A:Reference number: S38361; MUID:94032492; PMID:8218419

A:Accession: S38361

A:Molecule type: mRNA

A:Residues: 1-700

A:Cross-references: EMBL:L09120; NID:g402665; PIDN:AAAI6327.1; PID:g402666

R:Samis, J.A.; Back, D.W.; Graham, E.J.; Ellice, J.S.

submitted to the EMBL Data Library, February 1990

A:Reference number: S08650

A:Accession: S08650

A:Molecule type: DNA

A:Residues: 380-439 <SAM>

A:Cross-references: EMBL:X51772

C:Superfamily: calpain large chain; calmodulin repeat homology; calpain catalytic domain

C:Keywords: calcium binding; cysteine proteinase; duplication; EF hand; heterodimer; hyd

F:75-327/Domain: calpain catalytic domain homology <CALP>

F:529-560/Domain: calmodulin repeat homology <EF1>

F:572-604/Domain: calmodulin repeat homology <EF2>

F:605-634/Domain: calmodulin repeat homology <EF3>

F:637-669/Domain: calmodulin repeat homology <EF4>

F:105,262,286/Active site: Cys, His, Asn #status predicted

Query Match 52.5%; Score 52; DB 2; Length 700;

Best Local Similarity 60.0%; Pred. No. 4.7;

Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15

||||| : || : || :

Db 52 PAEPSSIGPEKLGYPY 66

RESULT 4

A41349

histone-specific transcription factor HBP1 - wheat

C:Species: Triticum sp. (wheat)

C>Date: 03-Apr-1992 #sequence_revision 03-Apr-1992 #text_change 09-Jun-2000

C:Accession: A41349

R:Tabata, T.; Takase, H.; Takayama, S.; Mikami, K.; Nakatsuka, A.; Kawata, T.; Nakayama,

Science 245, 965-967, 1989

A:Title: A protein that binds to a cis-acting element of wheat histone genes has a leuc

A:Reference number: A41349; MUID:89368924; PMID:2772648

A:Accession: A41349

A>Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-349 <TAB>

A:Cross-references: GB:M28704; NID:g170748; PIDN:AAA34293.1; PID:g170749

C:Superfamily: fava bean G-box-binding protein; fos/jun DNA-binding domain homology

C:Keywords: DNA binding; nucleus; transcription regulation

F:247-287/Domain: fos/jun DNA-binding domain homology <FJD>

Query Match

51.5%; Score 51; DB 2; Length 349;

Best Local Similarity 46.7%; Pred. No. 3.2;

Matches 7; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15

||||| : || : || :

Db 34 PEWPGQGYFAMPPH 48

RESULT 5

S77570

transcription factor HBP-1a(17) - wheat

N:Alternate names: basic leucine zipper protein HBP-1a(17)

C:Species: Triticum aestivum (common wheat)

C>Date: 19-Mar-1997 #sequence_revision 25-Apr-1997 #text_change 20-Jun-2000

C:Accession: S77570; S58693; S15346

R:Mikami, K.

submitted to the EMBL Data Library, August 1994

A:Reference number: S77570

A:Accession: S77570

A:Molecule type: DNA

A:Residues: 1-349 <WIK>

A:Cross-references: EMBL:D38111; NID:g1199789; PIDN:RAA07289.1; PID:g1199790

R:Mikami, K.; Katsura, M.; Ito, T.; Okada, K.; Shimura, Y.; Iwabuchi, M.

Mol. Gen. Genet. 248, 573-582, 1995

A:Title: Developmental and tissue-specific regulation of the gene for the wheat basi

A:Reference number: S58693; MUID:96027929; PMID:7476857

A:Accession: S58693

A:Molecule type: mRNA

A:Residues: 1-18 <MIW>

R:Tabata, T.; Nakayama, T.; Mikami, K.; Iwabuchi, M.

EMBO J. 10, 1459-1467, 1991

A:Title: HBP-1a and HBP-1b: leucine zipper-type transcription factors of wheat.

A:Reference number: S15346; MUID:91224097; PMID:2026143

A:Accession: S15346

A>Status: preliminary; nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-349 <TAB>

A:Cross-references: EMBL:X56781; NID:g21632; PIDN:CAA40101.1; PID:g21633

A>Note: the nucleotide sequence was submitted to the EMBL Data Library, November 1991

C:Genes:

C:Introns: 18/3; 40/3; 68/3; 114/3; 128/1; 147/2; 164/3; 177/1; 248/3; 274/3; :

C:Superfamily: fava bean G-box-binding protein; fos/jun DNA-binding domain homology

C:Keywords: DNA binding; leucine zipper; nucleus; transcription factor

F:247-287/Domain: fos/jun DNA-binding domain homology <FJD>

Query Match 51.5%; Score 51; DB 2; Length 349;

Best Local Similarity 46.7%; Pred. No. 3.2;

Matches 7; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15

||||| : || : || :

Db 34 PEWPGQGYFAMPPH 48

RESULT 6

C1HU82

calpain (EC 3.4.22.17) large chain 2 - human

N:Alternate names: calpain chain L-2; calpain II catalytic chain; high-calcium requi

C:Species: Homo sapiens (man)

C>Date: 21-Nov-1993 #sequence_revision 09-Aug-1997 #text_change 16-Jul-1999

C:Accession: S10590; A31218; A33529

R:Sorimachi, H.; Ohmi, S.; Emori, Y.; Kawasaki, H.; Saigo, T.C.; Ohno, S.; Minami, Y.

Biol. Chem. Hoppe-Seyler 371(Suppl.), 171-176, 1990

A:Title: A novel member of the calcium-dependent cysteine protease family.

A:Reference number: S10599; MUID:90380278; PMID:2400579

A:Accession: S10590

A:Molecule type: mRNA

A:Residues: 1-700 <SOR>

R:Imajoh, S.; Aoki, K.; Ohno, S.; Emori, Y.; Kawasaki, H.; Sugihara, H.; Suzuki, K.

Biochemistry 27, 8122-8128, 1988

A:Title: Molecular cloning of the cDNA for the large subunit of the high-Ca(2+)-requi

A:Reference number: A31218; MUID:89166474; PMID:2852952

A:Accession: A31218

```

F: 674-705/Domain: calmodulin repeat homology <EF5>
F: 2/Modified site: blocked amino end (Met) (in mature form) #status experimental
F: 108,265,289/active site: Cys, His, Asn #status predicted

Query Match          49.5%; Score 49; DB 1; Length 705;
Best Local Similarity 53.3%; Pred. No. 14;
Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEPVSYLGYEKLGPY 15
   | | : | : | : | : |
Db 55 PGPFTALGFKEKLGPY 69

RESULT 8
T23715
hypothetical protein M04C9.6c - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C:Accession: T23715
R:Burton, J.
submitted to the EMBL Data Library, December 1996
A:Reference number: Z19787
A:Accession: T23715
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-842 <WIL>
A:Cross-references: EMBL:Z83731; PIDN:CAB54273.1; GSPDB:GN00019; CESP:M04C9.6c
A:Experimental source: clone M04C9
C:Genetics:
A:Gene: CESP:M04C9.6c
A:Map position: 1
A:Introns: 71/3; 91/3; 114/3; 262/2; 322/2; 374/1; 500/1; 587/2; 645/2; 833/2

Query Match          49.5%; Score 49; DB 2; Length 842;
Best Local Similarity 42.9%; Pred. No. 16;
Matches 6; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2 EWPSYLGYEKLGPY 15
   | | : | : | : | : |
Db 145 KWSFIAYQQLGPF 158

RESULT 9
T23713
hypothetical protein M04C9.6b - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C:Accession: T23713
R:Burton, J.
submitted to the EMBL Data Library, December 1996
A:Reference number: Z19787
A:Accession: T23713
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-1160 <WIL>
A:Cross-references: EMBL:Z83731; PIDN:CAB06024.1; GSPDB:GN00019; CESP:M04C9.6b
A:Experimental source: clone M04C9
C:Genetics:
A:Gene: CESP:M04C9.6b
A:Map position: 1
A:Introns: 71/3; 91/3; 114/3; 262/2; 322/2; 374/1; 461/2; 519/2; 707/2; 727/3; 768/1

Query Match          49.5%; Score 49; DB 2; Length 1160;
Best Local Similarity 42.9%; Pred. No. 23;
Matches 6; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2 EWPSYLGYEKLGPY 15
   | | : | : | : | : |
Db 145 KWSFIAYQQLGPF 158

RESULT 10
T23714

```

```

hypothetical protein M04C9.6a - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C:Accession: T23714
R:Burton, J.
submitted to the EMBL Data Library, December 1996
A:Reference number: Z19787
A:Accession: T23714
A:Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: DNA
A:Residues: 1-1286 <WIL>
A:Cross-references: EMBL:Z19787; PIDN:CA806025.1; GSPDB:GN00019; CBSP:M04C9.6a
A:Experimental source: clone M04C9
C:Genetics:
A:Gene: CBSP:M04C9.6a
A:Map position: 1
A:Introns: 71/3; 91/3; 114/3; 262/2; 322/2; 374/1; 500/1; 587/2; 645/2; 833/2; 853/3; 89
Query Match 49.5%; Score 49; DB 2; Length 1286;
Best Local Similarity 42.9%; Pred. No. 26;
Matches 6; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 2 WPSYLYGKLGYY 15
      ||| : |||
Db 145 KWSFIAYQQLGFF 158

RESULT 11
B31807
Ig heavy chain V region (PAC1) - mouse
C:Species: Mus musculus (house mouse)
C:Date: 20-Jul-1989 #sequence_revision 20-Jul-1989 #text_change 23-May-1997
C:Accession: B31807
R:Raub, R.; Gould, R.J.; Garsky, V.M.; Ciccarone, T.M.; Hoxie, J.; Friedman, P.A.; Shatt
J. Biol. Chem. 264, 259-265, 1989
A:Title: A monoclonal antibody against the platelet fibrinogen receptor contains a sequ
A:Reference number: A31807; MUID:89079661; PMID:2909518
A:Accession: B31807
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-127 <TAU>
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-97/Domain: immunoglobulin homology <IMM>

Query Match 48.5%; Score 48; DB 2; Length 127;
Best Local Similarity 61.5%; Pred. No. 3.2;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
QY 4 PSYLYGKLGFFY 16
      ||| : |||
Db 100 PSYRYDGAGFY 112

RESULT 12
H90159
hypothetical protein lig [imported] - Sulfolobus solfataricus
C:Species: Sulfolobus solfataricus
C:Date: 24-May-2001 #sequence_revision 24-May-2001 #text_change 15-Jun-2001
C:Accession: H90159
R:She, Q.; Singh, R.K.; Confalonieri, F.; Zivanovic, Y.; Allard, G.; Avayez, M.J.; Chan-
Jong, I.; Jeffries, A.C.; Koser, C.J.; Medina, N.; Peng, X.; Thi-Ngoc, H.P.; Redder, P
arrett, R.A.; Ragan, M.A.; Sersen, C.W.; Van der Oost, J.
submitted to GenBank, April 2001
A:Description: Sulfolobus solfataricus complete genome.
A:Reference number: A99139
A:Accession: H90159
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-601 <KUR>
A:Cross-references: GB:AF006641; NID:g13813323; PIDN:AAK40535.1; GSPDB:GN00155
C:Genetics:
A:Gene: lig

```

```

C:Superfamily: DNA ligase
Query Match 48.5%; Score 48; DB 2; Length 601;
Best Local Similarity 63.6%; Pred. No. 16;
Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 3 WPSYLYGKLG 13
      || : ||| : ||
Db 50 WPDFLGYPELG 60

RESULT 13
D71221
probable morphine 6-dehydrogenase - Pyrococcus horikoshii
C:Species: Pyrococcus horikoshii
C:Date: 14-Aug-1998 #sequence_revision 14-Aug-1998 #text_change 21-Jul-2000
C:Accession: D71221
R:Kawabayashi, Y.; Sawada, M.; Horikawa, H.; Haikawa, Y.; Hino, Y.; Yamamoto, S.; S
M.; Ohtuku, Y.; Funahashi, T.; Tanaka, T.; Kudoh, Y.; Yamazaki, J.; Kushida, N.; Og
DNA Res. 5, 55-76, 1998
A:Title: Complete sequence and gene organization of the genome of a hyper-thermophil
A:Reference number: A71000; MUID:98344137; PMID:9679194
A:Accession: D71221
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA
A:Residues: 1-273 <RAW>
A:Cross-references: GB:AP000001; NID:g3236128; PIDN:BAA29099.1; PID:g3256416
A:Experimental source: strain OT3
A:Note: this accession replaces an interim accession for a sequence replaced by GenB
C:Genetics:
A:Gene: PH0031
C:Superfamily: aldehyde reductase

Query Match 48.0%; Score 47.5; DB 2; Length 273;
Best Local Similarity 41.7%; Pred. No. 8.6;
Matches 10; Conservative 1; Mismatches 2; Indels 11; Gaps 1;
QY 3 WPSYLYGK-----LGYPY 15
      ||| : |||
Db 85 WPSHFGYERAKKAKAKAKRLGTY 108

RESULT 14
AG0701
Orf 245 protein [imported] - Salmonella enterica subsp. enterica serovar Typhi (stra
C:Species: Salmonella enterica subsp. enterica serovar Typhi
A:Note: This species has also been called salmonella typhi
C:Date: 09-Nov-2001 #sequence_revision 09-Nov-2001 #text_change 18-Nov-2002
C:Accession: AG0701
R:Parkhill, J.; Dougan, G.; James, K.D.; Thomson, N.R.; Pickard, D.; Wain, J.; Churc
th, T.; Conington, P.; Cronin, A.; Davis, P.; Davies, R.M.; Dowd, L.; White, N.; Far
, S.; Moule, S.; O'Gaora, P.
Nature 413, 848-852, 2001
A:Authors: Parry, C.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens,
A:Title: Complete genome sequence of a multiple drug resistant Salmonella enterica s
A:Reference number: AB0502; MUID:21534947; PMID:11677608
A:Accession: AG0701
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-245 <PAR>
A:Cross-references: GB:AL513382; PIDN:CAD01984.1; PID:g16502824; GSPDB:GN00176
C:Genetics:
A:Gene: STY1741

Query Match 47.5%; Score 47; DB 2; Length 245;
Best Local Similarity 72.7%; Pred. No. 9.1;
Matches 8; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2 EWPSYLYGK 12
      ||| : |||
Db 172 EWPPLLGYNKL 182

```

```

RESULT 15
A48041
protein kinase (EC 2.7.1.37) cdc2-related CRK1 - Leishmania mexicana
C:Species: Leishmania mexicana
C>Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 10-Sep-1999
C:Accession: A48041; S31366
R:Mottram, J.C.; Kinnaird, J.H.; Shiels, B.R.; Tait, A.; Barry, J.D.
J. Biol. Chem. 268, 21044-21052, 1993
A:Title: A novel CDC2-related protein kinase from Leishmania mexicana, LmmCRK1, is post-
A:Reference number: A48041; MUID:94012652; PMID:8407941
A:Accession: A48041
A>Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-301 <MOT>
A:Cross-references: EMBL:X60385; NID:99539; PIDN:CAA42936.1; PID:99540
C:Superfamily: kinase-related transforming protein; protein kinase homology
C:Keywords: Atp; phosphotransferase
F:3-257/Domain: protein kinase homology <KIN>
F:11-19/Region: protein kinase Atp-binding motif
F:34,52,127,129/Active site: Lys, Glu, Asp, Lys #status predicted

Query Match          47.5%; Score 47; DB 1; Length 301;
Best Local Similarity 58.8%; Pred. No. 11;
Matches 10; Conservative 1; Mismatches 2; Indels 4; Gaps 1;

QY 1 PEWPSYL----GYEKLK 13
   ||| : | |||||
Db 251 PEWSNVLGSGVPGYKLG 267

```

Search completed: October 2, 2003, 14:36:38
Job time : 41 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 14:23:45 ; Search time 22 Seconds
(without alignments)
34.201 Million cell updates/sec

Title: US-09-763-848-1

Perfect score: 99
Sequence: 1 PEPFSLGYEKLGPYY 16

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 127863 seqs, 47026705 residues

Total number of hits satisfying chosen parameters: 127863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : SwissProt_41.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	56	56.6	700	1	Q08529 mus musculus
2	52	52.5	700	1	Q07009 rattus norv
3	51	51.5	349	1	P23922 triticum ae
4	51	51.5	700	1	P17655 homo sapien
5	49	49.5	705	1	P00789 gallus gall
6	48	48.5	600	1	Q97694 sulfolobus
7	48	48.5	601	1	Q99099 sulfolobus
8	48	48.5	601	1	Q98078 sulfolobus
9	47	47.5	301	1	Q06309 leishmania
10	46	46.5	340	1	P31765 haemophilus
11	45	45.5	611	1	P02773 rattus norv
12	45	45.5	700	1	Q92178 gallus gall
13	45	45.5	748	1	Q98404 homo sapien
14	44	44.4	268	1	P15773 malus domes
15	44	44.4	415	1	Q82441 pyrobaculum
16	44	44.4	687	1	P63014 rattus norv
17	43	43.4	120	1	P26799 streptomyce
18	43	43.4	378	1	P03877 saccharomyc
19	43	43.4	421	1	Q07384 african swi
20	43	43.4	482	1	Q93666 streptomyce
21	43	43.4	1295	1	Q45894 clostridium
22	42.5	42.9	735	1	P04967 zea mays (m
23	42	42.4	174	1	P08830 bombyx mori
24	42	42.4	196	1	P19666 tetrahymena
25	42	42.4	619	1	Q9unc6 mus musculu
26	42	42.4	702	1	Q9unc6 homo sapien
27	42	42.4	714	1	P07384 homo sapien
28	42	42.4	731	1	Q9unc2 xenopus lae
29	42	42.4	757	1	Q9hce7 homo sapien
30	42	42.4	1295	1	P10845 clostridium
31	41	41.4	440	1	A71A_MOUSE
32	41	41.4	870	1	PLSB_XYLFA
33	41	41.4	885	1	PLSB_XANAC

34	41	41.4	886	1	PLSB_XANCP
35	41	41.4	1228	1	NARG_BACSU
36	41	41.4	1245	1	NARG_ECOLI
37	41	41.4	1246	1	NARG_ECOLI
38	41	41.4	2214	1	POLG_CXA24
39	40.5	40.9	191	1	AMEX_HUMAN
40	40.5	40.9	565	1	ES10_RAT
41	40	40.4	246	1	IF28_HUMAN
42	40	40.4	323	1	HEMZ_HAEIN
43	40	40.4	488	1	STCW_EMENI
44	40	40.4	510	1	C304_DROME
45	40	40.4	600	1	DNL1_ACIAM

ALIGNMENTS

RESULT 1
CAN2_MOUSE
ID CAN2_MOUSE STANDARD; PRT: 700 AA.
AC Q08529; Q35518; Q54843;
DT 01-NOV-1997 (Rel. 35, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Calpain 2, large [catalytic] subunit precursor (EC 3.4.22.17)
DE (Calcium-activated neutral proteinase) (CAMP) (M-type) (M-calpain)
DE (Millimolar-calpain) (80 kDa M-calpain subunit) (CALP80).
GN CAPN2.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX NCBI_TaxID=10090;
[1]
PC SEQUENCE FROM N.A.
PC STRAIN=BALB/C;
RX MEDLINE=97480729; PubMed=9339374;
RA Dear T.N., Matena K., Vingron M., Boehm T.;
RA "A new subfamily of vertebrate calpains lacking a calmodulin-like
RA domain: implications for calpain regulation and evolution.";
RL Genomics 45:175-184(1997).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/C;
RA Ozaki Y.;
RL Submitted (OCT-1997) to the EMBL/GenBank/DBJ databases.
RN [3]
PC SEQUENCE FROM N.A.
PC TISSUE=CNS;
RA Glass J.D., Nash N.R., Dry I., Culver D., Wesselingh S.;
RA "Cloning of m-calpain from mouse nervous system.";
RL Submitted (JUL-1997) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: Calcium-regulated non-lysosomal thiol-protease which
CC catalyze limited proteolysis of substrates involved in
CC cytoskeletal remodeling and signal transduction (By similarity).
CC -1- CATALYTIC ACTIVITY: Preferential cleavage: Tyr-|-Xaa, Met-|-Xaa or
CC Arg-|-Xaa with leu or val as the P2 residue.
CC -1- COFACTOR: Binds 3 calcium ions.
CC -1- ENZYME REGULATION: Activated by 200-1000 micromolar concentrations
CC of calcium and inhibited by calpastatin.
CC -1- SUBUNIT: Heterodimer of a large (catalytic) and a small
CC (regulatory) subunit.
CC -1- SUBCELLULAR LOCATION: Cytoplasmic; Translocates to the plasma
CC membrane upon Ca++ binding.
CC -1- SIMILARITY: Contains 5 EF-hand calcium-binding domains.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY C2.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
CC or send an email to license@isb-sib.ch).

```

CC EMBL; Y10139; CAA71227.1; -.
DR EMBL; D38117; BAA22964.1; -.
DR EMBL; AF015038; AAB94029.1; -.
DR HSP; Q07009; 1DF0.
DR MEROPS; C02.002; -.
DR MGD; MGI:88264; Capn2.
DR InterPro; IPR002048; EF-hand.
DR InterPro; IPR001300; Protease_C2.
DR InterPro; IPR000169; SHprot_acsite.
DR Pfam; PF01067; Calpain_III; 1.
DR Pfam; PF00036; ehand; 2.
DR Pfam; PF00648; Peptidase_C2; 1.
DR PRINTS; PR00704; CALPAIN.
DR SMART; SM00720; calpain_III; 1.
DR SMART; SM00230; Cyspc; 1.
DR SMART; SM00054; EFh; 2.
DR PROSITE; PS00018; EF_HAND; 2.
DR PROSITE; PS00139; THIOL_PROTEASE_CYS; 1.
DR PROSITE; PS00639; THIOL_PROTEASE_HIS; FALSE NEG.
DR PROSITE; PS00640; THIOL_PROTEASE_ASN; FALSE NEG.
KW Hydrolase; Thiol protease; Calcium-binding; Repeat; Multigene family.
FT PROPEP 1 19 ANCHORS TO THE SMALL SUBUNIT (POTENTIAL).
FT CHAIN 20 700 CALPAIN 2, LARGE [CATALYTIC] SUBUNIT.
FT DOMAIN 20 355 CALPAIN.
FT DOMAIN 356 514 DOMAIN III.
FT DOMAIN 515 529 LINKER.
FT DOMAIN 530 700 DOMAIN IV.
FT CA_BIND 541 552 EF-HAND 1.
FT CA_BIND 585 596 EF-HAND 2.
FT CA_BIND 615 626 EF-HAND 3.
FT DOMAIN 680 661 ANCESTRAL CALCIUM SITE 4 (POTENTIAL).
FT DOMAIN 680 691 ANCESTRAL CALCIUM SITE 5 (POTENTIAL).
FT ACT_SITE 105 105 BY SIMILARITY.
FT ACT_SITE 262 262 BY SIMILARITY.
FT ACT_SITE 286 286 BY SIMILARITY.
FT CONFLICT 194 194 A -> T (IN REF. 1).
FT CONFLICT 212 212 A -> G (IN REF. 2).
FT CONFLICT 402 402 E -> G (IN REF. 1).
SQ SEQUENCE 700 AA; 79871 MW; 682146B290968316 CRC64;

Query Match 56.6%; Score 56; DB 1; Length 700;
Best Local Similarity 66.7%; Pred. No. 0.76;
Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEPVSIVGVKGLPY 15
DB 52 PALPSSLGKELGYP 66

RESULT 2
CAN2_RAT STANDARD; PRT; 700 AA.
AC Q07009;
DT 01-JUN-1994 (Rel. 29, Created)
DT 01-JUN-1994 (Rel. 25, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Calpain 2, large [catalytic] subunit precursor (EC 3.4.22.17)
DE (Calcium-activated neutral proteinase) (CANP) (M-type) (M-calpain)
DE (Millimolar-calpain).
GN CAPN2.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.
OX NCBI_TaxID=10116;
[1]
RP SEQUENCE FROM N.A.
RX MEDLINE=94032492; PubMed=8218419;
RA Deluca C.I., Davies P.L., Samis J.A., Elce J.S.;
RT "Molecular cloning and bacterial expression of cDNA for rat calpain
RL Ii 80 kDa subunit.";
RL Biochim. Biophys. Acta 1216:81-93(1993).
RN [2]

```

```

RP PARTIAL SEQUENCE.
RX MEDLINE=21240297; PubMed=11342050;
RA Moldoveanu T., Hosfield C.M., Jia Z., Elce J.S., Davies P.L.;
RT "Ca(2+)-induced structural changes in rat m-calpain revealed by
partial proteolysis.";
RL Biochim. Biophys. Acta 1545:245-254(2001).
RN [3]
RP MUTAGENESIS OF LYS-230; LYS-234 AND GLU-504.
RX MEDLINE=21269273; PubMed=11102442;
RA Hosfield C.M., Moldoveanu T., Davies P.L., Elce J.S., Jia Z.;
RT "Calpain mutants with increased Ca2+ sensitivity and implications for
the role of the C(2)-like domain.";
RL J. Biol. Chem. 276:7404-7407(2001).
RN [4]
RP MUTAGENESIS OF CYS-105; HIS-262; ASN-286 AND TRP-288.
RX MEDLINE=95361909; PubMed=7635186;
RA Arthur J.S., Gauthier S., Elce J.S.;
RT "Active site residues in m-calpain: identification by site-directed
mutagenesis.";
RL FEBS Lett. 368:397-400(1995).
RN [5]
RP X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS).
RX MEDLINE=20069318; PubMed=10601010;
RA Hosfield C.M., Elce J.S., Davies P.L., Jia Z.;
RT "Crystal structure of calpain reveals the structural basis for
Ca(2+)-dependent protease activity and a novel mode of enzyme
activation.";
RL EMBO J. 18:6880-6889(1999).
CC -!- FUNCTION: Calcium-regulated non-lysosomal thiol-protease which
catalyze limited proteolysis of substrates involved in
cytoskeletal remodelling and signal transduction.
CC -!- CATALYTIC ACTIVITY: Preferential cleavage: Tyr-I-Xaa, Met-I-Xaa or
Arg-I-Xaa with leu or val as the P2 residue.
CC -!- COFACTOR: Binds 3 calcium ions.
CC -!- ENZYME REGULATION: Activated by 200-1000 micromolar concentrations
of calcium and inhibited by calpastatin.
CC -!- SUBUNIT: Heterodimer of a large (catalytic) and a small
(regulatory) subunit.
CC -!- SUBCELLULAR LOCATION: Cytoplasmic; Translocates to the plasma
membrane upon Ca++ binding.
CC -!- SIMILARITY: Contains 5 EF-hand calcium-binding domains.
CC -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY C2.
-----
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
DR EMBL; I09120; AAA16327.1; -.
DR PIR; S38361; S38361.
DR PDB; 1DF0; 26-NOV-01.
DR MEROPS; C02.002; -.
DR InterPro; IPR002048; EF-hand.
DR InterPro; IPR001300; Protease_C2.
DR InterPro; IPR000169; SHprot_acsite.
DR Pfam; PF01067; Calpain_III; 1.
DR Pfam; PF00036; ehand; 3.
DR Pfam; PF00648; Peptidase_C2; 1.
DR PRINTS; PR00704; CALPAIN.
DR SMART; SM00720; calpain_III; 1.
DR SMART; SM00230; Cyspc; 1.
DR SMART; SM00054; EFh; 2.
DR PROSITE; PS00018; EF_HAND; 2.
DR PROSITE; PS00139; THIOL_PROTEASE_CYS; 1.
DR PROSITE; PS00639; THIOL_PROTEASE_HIS; FALSE NEG.
DR PROSITE; PS00640; THIOL_PROTEASE_ASN; FALSE NEG.
KW Hydrolase; Thiol protease; Calcium-binding; Repeat; Multigene family;
3D-structure.
FT PROPEP 1 19 ANCHORS TO THE SMALL SUBUNIT (POTENTIAL).
FT CHAIN 20 700 CALPAIN 2, LARGE [CATALYTIC] SUBUNIT.

```

```

FT DOMAIN 20 355
FT DOMAIN 356 514
FT DOMAIN 515 529
FT DOMAIN 530 700
FT CA_BIND 541 552
FT CA_BIND 585 596
FT CA_BIND 615 626
FT DOMAIN 650 661
FT DOMAIN 680 691
FT ACT_SITE 105 103
FT ACT_SITE 262 262
FT ACT_SITE 286 286
FT MUTAGEN 105 105
FT MUTAGEN 226 226
FT MUTAGEN 230 230
FT MUTAGEN 230 230
FT MUTAGEN 234 234
FT MUTAGEN 234 234
FT MUTAGEN 262 262
FT MUTAGEN 286 286
FT MUTAGEN 288 288
FT MUTAGEN 504 504
FT SEQUENCE 700 AA; 79919 MW; 296B0DC3BEEF5B90 CRC64;

Query Match 52.5%; Score 52; DB 1; Length 700;
Best Local Similarity 60.0%; Pred. No. 3;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15
DB 52 PALPSSLGFKELGYPY 66

RESULT 3
HBPA_WHEAT
ID HBPA_WHEAT STANDARD; PRT; 349 AA.
AC P23922;
DT 01-MAR-1992 (Rel. 21, Last sequence update)
DT 01-MAR-1992 (Rel. 21, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Transcription factor HBP-1a (Histone-specific transcription factor Hbp1).
OS Triticum aestivum (Wheat).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poaceae;
OC Triticeae; Triticum.
OC NCBI_TaxID=4565;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=91224097; PubMed=2026143;
RA Tabata T., Nakayama T., Mikami K., Iwabuchi M.;
RT "HBP-1a and HBP-1b: leucine zipper-type transcription factors of wheat."
RL EMBO J. 10:1459-1467(1991).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=89368924; PubMed=2772648;
RA Tabata T., Takase H., Takayama S., Mikami K., Nakatsuka A., Kawata T., Nakayama T., Iwabuchi M.;
RT "Developmental and tissue-specific regulation of the gene for the wheat basic/leucine zipper protein HBP-1a(17) in transgenic Arabidopsis plants."
RL Mol. Gen. Genet. 248:573-582(1995).
RN [3]
RP SEQUENCE FROM N.A.
RX STRAIN=cv. Horoshirikonugi;
RA Mikami K., Katsura M., Ito T., Okada K., Shimura Y., Iwabuchi M.;
RT "Developmental and tissue-specific regulation of the gene for the wheat basic/leucine zipper protein HBP-1a(17) in transgenic Arabidopsis plants."
RL Mol. Gen. Genet. 248:573-582(1995).
CC -!- FUNCTION: BIND TO THE HEXAMER MOTIF 5'-ACGTCA-3' OF HISTONE GENE PROMOTERS.

CC -!- SUBUNIT: Binds DNA as a dimer.
CC -!- SUBCELLULAR LOCATION: Nuclear.
CC -!- SIMILARITY: Belongs to the bZIP family.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC EMBL; X56781; CAA40101.1; -.
CC EMBL; M28704; AAA34293.1; -.
CC EMBL; D38111; BAA07289.1; -.
CC PIR; S77570; S77570.
CC HSSP; P03069; ZDGC.
CC TRANSFAC; T00354; -.
CC TRANSFAC; T00937; -.
CC InterPro; IPR004827; TF_bZIP.
CC Pfam; PF00170; bZIP; 1.
CC SMART; SM00338; BRZ; 1.
CC PROSITE; PS00217; bZIP; 1.
CC PROSITE; PS00036; bZIP_BASIC; 1.
CC Transcription regulation; DNA-binding; Activator; Nuclear protein.
FT DNA_BIND 254 273 BASIC MOTIF.
FT DOMAIN 280 294 LEUCINE-ZIPPER.
FT SEQUENCE 349 AA; 36743 MW; 51FC8E039DF7F7A CRC64;

Query Match 51.5%; Score 51; DB 1; Length 349;
Best Local Similarity 46.7%; Pred. No. 2;
Matches 7; Conservative 3; Mismatches 5; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15
DB 34 PEWPFQGYVAMPPH 48

RESULT 4
CAN2_HUMAN
ID CAN2_HUMAN STANDARD; PRT; 700 AA.
AC P17655; Q16738; Q8WU26; Q9HBB1;
DT 01-AUG-1990 (Rel. 15, Created)
DT 01-AUG-1990 (Rel. 15, Last sequence update)
DT 15-SEP-2003 (Rel. 42, Last annotation update)
DE Calpain 2, large [catalytic] subunit precursor (EC 3.4.22.17) (Calcium-activated neutral proteinase) (CANP) (M-type) (M-calpain) (Millimolar-calpain) (Calpain large polypeptide L2).
DE CAPN2 OR CAPNL2.
GN CAPN2
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=89166474; PubMed=2852952;
RA Inaich S., Aoki K., Ohno S., Emori Y., Kawasaki H., Sugihara H., Suzuki K.;
RT "Molecular cloning of the cDNA for the large subunit of the high-Ca2+-requiring form of human Ca2+-activated neutral protease."
RL Biochemistry 27:8122-8128(1988).
RN [2]
RP SEQUENCE FROM N.A.
RX TISSUE=Astrocytoma;
RA Ye Z., Connor J.R.;
RT "cDNA cloning by amplification of circularized first strand cDNAs reveals non-TRE-regulated iron-responsive mRNAs."
RL Biochem. Biophys. Res. Commun. 275:223-227(2000).
RN [3]
RP SEQUENCE FROM N.A.
RX TISSUE=Pancreas;
RA MEDLINE=22388257; PubMed=12477932;

```


RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Atschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.W., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.B., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Murny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RA "Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences.";
RA Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [4]
RN SEQUENCE OF 1-79 FROM N.A.
RC TISSUE=Lymph node;
RX MEDLINE=89197947; PubMed=2539381;
RA Hata A., Ohno S., Akita Y., Suzuki K.;
RA "Tandemly reiterated negative enhancer-like elements regulate
transcription of a human gene for the large subunit of calcium-
dependent protease.";
RT J. Biol. Chem. 264:6404-6411(1989).
RN [5]
RN X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).
RX MEDLINE=20105516; PubMed=10639123;
RA Strobl S., Fernandez-Catalan C., Braun M., Huber R., Masumoto H.,
RA Nakagawa K., Irie A., Sorimachi H., Bourenkow G., Bartunik H.,
RA Suzuki K., Bode W.;
RA "The crystal structure of calcium-free human m-calpain suggests an
electrostatic switch mechanism for activation by calcium.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:588-592(2000).
CC -!- FUNCTION: Calcium-regulated non-lysosomal thiol-protease which
catalyze limited proteolysis of substrates involved in
cytoskeletal remodeling and signal transduction.
CC -!- CATALYTIC ACTIVITY: Preferential cleavage: Tyr-|-Xaa, Met-|-Xaa or
Arg-|-Xaa with Leu or Val as the P2 residue.
CC -!- COFACTOR: Binds 3 calcium ions.
CC -!- ENZYME REGULATION: Activated by 200-1000 micromolar concentrations
of calcium and inhibited by calpastatin.
CC -!- SUBUNIT: Heterodimer of a large (catalytic) and a small
(regulatory) subunit.
CC -!- SUBCELLULAR LOCATION: Cytoplasmic; Translocates to the plasma
membrane upon Ca++ binding.
CC -!- SIMILARITY: Contains 5 EF-hand calcium-binding domains.
CC -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY C2.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
or send an email to license@isb-sib.ch).
CC -----
DR ENBL; M23254; AAA35645.1; -;
DR ENBL; AF261089; AAF99682.1; -;
DR ENBL; BC021303; AAH21303.1; -;
DR ENBL; J04700; AAA52760.1; -;
DR PIR; S10590; C1HUH2.
DR PDB; 1KFU; 07-DEC-01.
DR PDB; 1KFX; 07-DEC-01.
DR MEROPS; C02.002; -;
DR Genew; HGNC:1479; CAPN2.
DR MIM; 114230; -;
DR GO; GO:0008234; F:cysteine-type peptidase activity; TAS.
DR InterPro; IPR002048; EF-hand.

DR InterPro; IPR001300; Protease_C2.
DR InterPro; IPR00169; SHProt_acsite.
DR Pfam; PF01067; Calpain_III; 1.
DR Pfam; PF00036; efhand; 3.
DR Pfam; PF00848; peptidase_C2; 1.
DR PRINTS; PR00704; CALPAIN.
DR SMART; SM00720; calpain_III; 1.
DR SMART; SM00230; Cyspc; 1.
DR PROSITE; PS00018; EF_HAND; 2.
DR PROSITE; PS00139; THIOL PROTEASE_CYS; 1.
DR PROSITE; PS00639; THIOL PROTEASE_HIS; FALSE NEG.
DR PROSITE; PS00940; THIOL PROTEASE ASN; FALSE NEG.
KW Hydrolase; Thiol protease; calcium-binding; Repeat; Multigene family;
KW 3D-structure; Polymorphism.
FT PROPEP 1 19
FT CHAIN 20 700 ANCHORS TO THE SMALL SUBUNIT (POTENTIAL).
FT DOMAIN 27 355 CALPAIN 2, LARGE [CATALYTIC] SUBUNIT.
FT DOMAIN 356 514 CALPAIN.
FT DOMAIN 515 529 LINKER III.
FT DOMAIN 530 700 DOMAIN IV.
FT CA_BIND 541 552 EF-HAND 1.
FT CA_BIND 585 596 EF-HAND 2.
FT CA_BIND 615 626 EF-HAND 3.
FT DOMAIN 650 661 ANCESTRAL CALCIUM SITE 4 (POTENTIAL).
FT DOMAIN 680 691 ANCESTRAL CALCIUM SITE 5 (POTENTIAL).
FT ACT_SITE 105 105 BY SIMILARITY.
FT ACT_SITE 262 262 BY SIMILARITY.
FT ACT_SITE 286 286 BY SIMILARITY.
FT VARIANT 22 22 E -> D (IN dbSNP:25655).
FT VARIANT 568 568 /FTID=VAR_014435.
FT VARIANT 568 568 K -> Q (IN dbSNP:17599).
FT CONFLICT 68 68 S -> G (IN REF. 4).
FT CONFLICT 73 74 IE -> MR (IN REF. 1).
FT CONFLICT 256 256 Q -> K (IN REF. 2).
FT CONFLICT 300 300 N -> S (IN REF. 2).
FT CONFLICT 534 534 V -> F (IN REF. 3).
FT HELIX 4 16
FT TURN 17 19
FT TURN 22 23
FT STRAND 25 26
FT STRAND 27 29
FT HELIX 32 42
FT TURN 43 43
FT TURN 55 58
FT TURN 69 70
FT STRAND 73 76
FT HELIX 78 81
FT STRAND 86 86
FT STRAND 97 98
FT TURN 101 102
FT TURN 105 113
FT TURN 114 115
FT HELIX 118 121
FT TURN 122 124
FT TURN 136 137
FT STRAND 138 144
FT STRAND 149 155
FT STRAND 158 161
FT TURN 162 163
FT STRAND 164 165
FT STRAND 169 170
FT STRAND 175 175
FT HELIX 177 187
FT TURN 188 189
FT HELIX 192 194
FT TURN 196 197
FT HELIX 200 206
FT TURN 207 208
FT STRAND 211 216
FT TURN 217 218
FT TURN 222 223
FT HELIX 224 232


```

ID DNLI_SULTO STANDARD; PRT; 600 AA.
AC Q976G4;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Thermotable DNA ligase (EC 6.5.1.1) (Polydeoxyribonucleotide
DE synthase [ATP]).
GN LIG OR ST0223.
OS Sulfolobus tokodaii.
OC Archaea; Crenarchaeota; Thermoprotei; Sulfolobales; Sulfolobaceae;
OC Sulfolobus.
OX NCBI_TaxID=111955;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=JCM 10545 / 7;
RX MEDLINE=21456156; PubMed=11572479;
RA Kawarabayashi Y., Hino Y., Horikawa H., Jin-no K., Takahashi M.,
RA Sekine M., Baba S.-I., Ankai A., Kosugi H., Hosoyama A., Fukui S.,
RA Nagai Y., Nishijima K., Otsuka R., Nakazawa H., Takamiya M., Kato Y.,
RA Yoshizawa T., Tanaka T., Kudoh Y., Yamazaki J., Kushida N., Oguchi A.,
RA Aoki K.-I., Masuda S., Yanagii M., Nishimura M., Yamagishi A.,
RA Oshima T., Kikuchi H.;
RT "Complete genome sequence of an aerobic thermophilic
RT Crenarchaeon, Sulfolobus tokodaii strain7.";
RL DNA Res. 8:123-140(2001).
CC -1- FUNCTION: THIS PROTEIN SEALS DURING DNA REPLICATION, DNA
CC RECOMBINATION AND DNA REPAIR NICKS IN DOUBLE-STRANDED DNA (BY
CC SIMILARITY).
CC -1- CATALYTIC ACTIVITY: ATP + {deoxyribonucleotide}(N) +
CC {deoxyribonucleotide}(M) = AMP + diphosphate +
CC {deoxyribonucleotide}(N+M).
CC -1- SIMILARITY: BELONGS TO THE ATP-DEPENDENT DNA LIGASE FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
CC EMBL; AF000981; BAB65183.1; -.
CC HAMAP; MF_00407; -.
CC InterPro; IPR000977; DNA_ligase.
CC Pfam; PF01068; DNA_ligase; 1.
CC Pfam; PF04679; DNA_ligase_A; 1.
CC Pfam; PF04675; DNA_ligase_A_N; 1.
CC TIGRfams; TIGR00574; dnl1; 1.
CC PROSITE; PS00697; DNA_LIGASE_A1; 1.
CC PROSITE; PS00333; DNA_LIGASE_A2; 1.
CC PROSITE; PS0160; DNA_LIGASE_A3; 1.
CC DNA repair; DNA replication; DNA recombination; Cell division; Ligase;
CC ATP-binding. 260 260 AMP (BY SIMILARITY).
CC BINDING 260 260
CC SEQUENCE 600 AA; 68025 MW; 9D85DA4458000539 CRC64;
CC
CC Query Match 48.5%; Score 48; DB 1; Length 600;
CC Best Local Similarity 63.6%; Pred. No. 10;
CC Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
CC
CC QY 3 WFSYLGYEKLG 13
CC DB 50 WPDFLGYPELG 60
CC
CC RESULT 7
CC DNLI_SULSH STANDARD; PRT; 601 AA.
CC
CC ID DNLI_SULSH
CC AC Q9P9K3;
CC DT 16-OCT-2001 (Rel. 40, Created)
CC DT 16-OCT-2001 (Rel. 40, Last sequence update)
CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
CC DE Thermotable DNA ligase (EC 6.5.1.1) (Polydeoxyribonucleotide
CC synthase [ATP]).
CC GN LIG OR ST0223.
CC OS Sulfolobus solfataricus.
CC Archaea; Crenarchaeota; Thermoprotei; Sulfolobales; Sulfolobaceae;
CC Sulfolobus.
CC NCBI_TaxID=2287;
CC [1]
CC RP SEQUENCE FROM N.A.
CC RC STRAIN=ATCC 35092 / DSM 1617 / P2;
CC RX MEDLINE=21332296; PubMed=11427726;
CC RA She Q., Singh R.K., Confalonieri F., Zivanovic Y., Allard G.,
CC Aweyaz M.J., Chan-Weiner C.-Y., Clausen I.G., Curtis B.A.,
CC De Moors A., Erasus G., Fletcher C., Gordon P.M.K.,
CC Heikamp-de Jong I., Jeffries A.C., Kozera C.J., Medina N., Peng X.,

```

```

DE synthase [ATP]).
GN LIG.
OS Sulfolobus shibatae.
OC Archaea; Crenarchaeota; Thermoprotei; Sulfolobales; Sulfolobaceae;
OC Sulfolobus.
OX NCBI_TaxID=2286;
RN [1]
RP SEQUENCE FROM N.A.
RA Lai X., Shao H., Huang L.;
RT "A thermophilic DNA ligase from Sulfolobus shibatae.";
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: THIS PROTEIN SEALS DURING DNA REPLICATION, DNA
CC RECOMBINATION AND DNA REPAIR NICKS IN DOUBLE-STRANDED DNA (BY
CC SIMILARITY).
CC -1- CATALYTIC ACTIVITY: ATP + {deoxyribonucleotide}(N) +
CC {deoxyribonucleotide}(M) = AMP + diphosphate +
CC {deoxyribonucleotide}(N+M).
CC -1- SIMILARITY: BELONGS TO THE ATP-DEPENDENT DNA LIGASE FAMILY.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
CC EMBL; AF242877; AAF61267.1; -.
CC HAMAP; MF_00407; -.
CC InterPro; IPR000977; DNA_ligase.
CC Pfam; PF01068; DNA_ligase; 1.
CC Pfam; PF04679; DNA_ligase_A; 1.
CC Pfam; PF04675; DNA_ligase_A_N; 1.
CC TIGRfams; TIGR00574; dnl1; 1.
CC PROSITE; PS00697; DNA_LIGASE_A1; 1.
CC PROSITE; PS00333; DNA_LIGASE_A2; 1.
CC PROSITE; PS0160; DNA_LIGASE_A3; 1.
CC DNA repair; DNA replication; DNA recombination; Cell division; Ligase;
CC ATP-binding. 260 260 AMP (BY SIMILARITY).
CC BINDING 260 260
CC SEQUENCE 601 AA; 67646 MW; C029AC84AB39AFD4 CRC64;
CC
CC Query Match 48.5%; Score 48; DB 1; Length 601;
CC Best Local Similarity 63.6%; Pred. No. 10;
CC Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
CC
CC QY 3 WFSYLGYEKLG 13
CC DB 50 WPDFLGYPELG 60
CC
CC RESULT 8
CC DNLI_SULSO STANDARD; PRT; 601 AA.
CC
CC ID DNLI_SULSO
CC AC Q980T8;
CC DT 28-FEB-2003 (Rel. 41, Created)
CC DT 28-FEB-2003 (Rel. 41, Last sequence update)
CC DT 28-FEB-2003 (Rel. 41, Last annotation update)
CC DE Thermotable DNA ligase (EC 6.5.1.1) (Polydeoxyribonucleotide
CC synthase [ATP]).
CC GN LIG OR SSO0189.
CC OS Sulfolobus solfataricus.
CC Archaea; Crenarchaeota; Thermoprotei; Sulfolobales; Sulfolobaceae;
CC Sulfolobus.
CC NCBI_TaxID=2287;
CC [1]
CC RP SEQUENCE FROM N.A.
CC RC STRAIN=ATCC 35092 / DSM 1617 / P2;
CC RX MEDLINE=21332296; PubMed=11427726;
CC RA She Q., Singh R.K., Confalonieri F., Zivanovic Y., Allard G.,
CC Aweyaz M.J., Chan-Weiner C.-Y., Clausen I.G., Curtis B.A.,
CC De Moors A., Erasus G., Fletcher C., Gordon P.M.K.,
CC Heikamp-de Jong I., Jeffries A.C., Kozera C.J., Medina N., Peng X.,

```

```

RA Thi-Ngoc H.P., Redder P., Schenk M.E., Theriault C., Tolstrup N.,
RA Charlebois R.L., Doolittle W.F., Duquet M., Gaasterland T.,
RA Garrett R.A., Ragan M.A., Sengen C.W., Van der Oost J.,
RT "The complete genome of the crenarchaeon Sulfolobus solfataricus P2.";
RC Proc. Natl. Acad. Sci. U.S.A. 98:7835-7840(2001).
CC -!- FUNCTION: THIS PROTEIN SEALS DURING DNA REPLICATION, DNA
CC RECOMBINATION AND DNA REPAIR NICKS IN DOUBLE-STRANDED DNA (BY
CC SIMILARITY).
CC -!- CATALYTIC ACTIVITY: ATP + {deoxyribonucleotide}(N) +
CC {deoxyribonucleotide}(NM) = AMP + diphosphate +
CC {deoxyribonucleotide}(NM).
CC -!- SIMILARITY: BELONGS TO THE ATP-DEPENDENT DNA LIGASE FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: AE006656; AAK40535.1; -.
CC F1R: H90159; H90159.
CC HAMAP: MF_004077; 1.
CC InterPro: IPR000977; DNA_ligase.
CC Pfam: PF01068; DNA_ligase_1.
CC Pfam: PF04679; DNA_ligase_A_C; 1.
CC Pfam: PF04675; DNA_ligase_A_N; 1.
CC TIGRfams: TIGR00574; dnll; 1.
CC PROSITE: PS00697; DNA_LIGASE_A1; 1.
CC PROSITE: PS00333; DNA_LIGASE_A2; 1.
CC PROSITE: PS50160; DNA_LIGASE_A3; 1.
CC DNA repair; DNA replication; DNA recombination; Cell division; Ligase;
CC ATP-binding; Complete proteome.
CC BINDING 260 260 AMP (BY SIMILARITY).
CC SEQUENCE 601 AA; 67732 MW; DA6814F4A6F0546E CRC64;
Query Match 48.5%; Score 48; DB 1; Length 601;
Best Local Similarity 63.6%; Pred. No. 10;
Matches 7; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 3 WPSVLGYEKLIG 13
DB 50 WPDFLIGPELG 60
RESULT 9
ID CRK1_LEIME STANDARD; PRT; 301 AA.
AC Q06309;
DT 01-OCT-1994 (Rel. 30, Created)
DT 01-OCT-1994 (Rel. 30, Last sequence update)
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Cell division protein kinase 2 homolog CRK1 (EC 2.7.1.-).
GN CRK1.
OS Leishmania mexicana
OC Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae; Leishmania.
OX NCBI_TaxID=5665;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-Ssp. Mexicana;
RX MEDLINE=94012652; PubMed=8407941;
RA Mottram J.C., Kinaird J.H., Shiels B.R., Tait A., Barry J.D.;
RT "A novel CDC2-related protein kinase from Leishmania mexicana,
RL ImmCRK1, is post-translationally regulated during the life cycle.";
RL J. Biol. Chem. 268:21044-21052(1993).
CC -!- FUNCTION: MAY BE INVOLVED IN SOME STAGE-SPECIFIC ROLE IN THE
CC PROMASTIGOTE CELL CYCLE.
CC -!- ENZYME REGULATION: PHOSPHORYLATION AT THR-15 OR TYR-16 INACTIVATES
CC THE ENZYME, WHILE PHOSPHORYLATION AT THR-160 ACTIVATES IT (BY
CC SIMILARITY).
CC -!- SUBUNIT: FORMS A STABLE BUT NON-COVALENT COMPLEX WITH A REGULATORY
CC SUBUNIT AND WITH A CYCLIN (BY SIMILARITY).

```

```

CC -!- DEVELOPMENTAL STAGE: EXPRESSED IN ALL LIFE CYCLE STAGES,
CC PROMASTIGOTE, METACYCLIC AND AMASTIGOTE FORMS BUT IS FOUND
CC IN THE ACTIVE FORM ONLY IN THE PROMASTIGOTE STAGE.
CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
CC CDC2/CDCX SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL: X60385; CAA42936.1; -.
CC F1R: A48041; A48041.
CC HSP: P24941; LB0H.
CC InterPro: IPR000719; Prot_kinase.
CC InterPro: IPR002290; Ser_Thr_kinase.
CC Pfam: PF00069; pkinase; 1.
CC ProDom: PD000001; Prot_kinase; 1.
CC SMART: SM00220; S_TKC; 1.
CC PROSITE: PS00107; PROTEIN_KINASE_ATP; 1.
CC PROSITE: PS00108; PROTEIN_KINASE_ST; 1.
CC PROSITE: PS50011; PROTEIN_KINASE_DOM; 1.
CC Phosphatase; Serine/threonine-protein kinase; ATP-binding;
CC Phosphorylation.
CC DOMAIN 5 297 PROTEIN KINASE.
CC NP_BIND 11 19 ATP (BY SIMILARITY).
CC BINDING 34 34 ATP (BY SIMILARITY).
CC ACT_SITE 127 127 BY SIMILARITY.
CC MOD_RES 15 15 PHOSPHORYLATION.
CC MOD_RES 16 16 PHOSPHORYLATION.
CC MOD_RES 160 160 PHOSPHORYLATION (BY CAK) (BY SIMILARITY).
CC SEQUENCE 301 AA; 34473 MW; 58EB39D06D88461 CRC64;
Query Match 47.5%; Score 47; DB 1; Length 301;
Best Local Similarity 58.8%; Pred. No. 74;
Matches 10; Conservative 1; Mismatches 2; Indels 4; Gaps 1;
QY 1 PEWPSYL---GYEKLIG 13
DB 251 PEWSNVLGVPGEYKLG 267
RESULT 10
ID G3LM_HAEIN STANDARD; PRT; 340 AA.
AC P31765;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Aldose 1-epimerase (EC 5.1.3.3) {Mutarotase}.
GN G3LM OR MRO OR HI0818.
OS Haemophilus influenzae.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
OC Pasteurellaceae; Haemophilus.
OX NCBI_TaxID=727;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-Rd / KW20 / ATCC 51907;
RX MEDLINE=95350630; PubMed=7542800;
RA Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F.,
RA Kerlavage A.R., Bult C.J., Tomb J.-F., Dougherty B.A., Merrick J.M.,
RA McKenney K., Sutton G., Fitzhugh W., Fields C.A., Gocayne J.D.,
RA Scott J.D., Shirley R., Liu L.-I., Glodek A., Kelley J.M.,
RA Weidman J.F., Phillips C.A., Spriggs T., Hedblom E., Cotton M.D.,
RA Utterback T.R., Hanna M.C., Nguyen D.T., Saudek D.M., Brandon R.C.,
RA Fine L.D., Fritchman J.L., Fuhrmann J.L., Geoghagen N.S.M.,
RA Gnehm C.L., McDonald L.A., Small R.V., Fraser C.M., Smith H.O.,
RA Venter J.C.;
RT "Whole-genome random sequencing and assembly of Haemophilus influenzae
RT Rd.";

```



```

FT DISULFID 150 195 BY SIMILARITY.
FT DISULFID 194 203 BY SIMILARITY.
FT DISULFID 226 272 BY SIMILARITY.
FT DISULFID 271 279 BY SIMILARITY.
FT DISULFID 291 305 BY SIMILARITY.
FT DISULFID 304 315 BY SIMILARITY.
FT DISULFID 386 395 BY SIMILARITY.
FT DISULFID 418 464 BY SIMILARITY.
FT DISULFID 463 474 BY SIMILARITY.
FT DISULFID 487 503 BY SIMILARITY.
FT DISULFID 502 513 BY SIMILARITY.
FT DISULFID 540 585 BY SIMILARITY.
FT DISULFID 584 593 BY SIMILARITY.
FT CARBOHYD 117 117 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 253 253 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CONFLICT 556 557 IN -> VG (IN REF. 6).
SQ SEQUENCE 611 AA; 68386 MW; 7DC54624B7245C41 CRC64;

Query Match 45.5%; Score 45; DB 1; Length 611;
Best Local Similarity 87.5%; Pred. No. 29;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 9 YKLGPPY 16
Db 421 YKLGPPY 428

RESULT 12
CAN2_CHICK STANDARD; PRT; 700 AA.
AC Q32178;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Calpain 2, large [catalytic] subunit precursor (PC 3.4.22.17)
DE (Calcium-activated neutral proteinase) (CAMP) (M-type) (M-calpain)
DE (Molluscan-calpain).
GN CAPN2.
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Muscle;
RX MEDLINE=95260862; PubMed=7742367;
RA Sorinachi H., Tsukahara T., Okada-Ban M., Sugita H., Ishiura S.,
RA Suzuki K.;
RT Identification of a third ubiquitous calpain species -- chicken
muscle expresses four distinct calpains."
RL Biochim. Biophys. Acta 1261:381-393(1995).
CC -I- FUNCTION: Calcium-regulated non-lysosomal thiol-protease which
catalyze limited proteolysis of substrates involved in
cytoskeletal remodeling and signal transduction (By similarity).
CC -I- CATALYTIC ACTIVITY: Preferential cleavage: Tyr-I-Xaa, Met-I-Xaa or
Arg-I-Xaa with Leu or Val as the P2 residue.
CC -I- COFACTOR: Binds 3 calcium ions.
CC -I- ENZYME REGULATION: Activated by 200-1000 micromolar concentrations
of calcium and inhibited by calpastatin.
CC -I- SUBUNIT: Heterodimer of a large (catalytic) and a small
(regulatory) subunit.
CC -I- SUBCELLULAR LOCATION: Cytoplasmic; Translocates to the plasma
membrane upon Ca++ binding.
CC -I- SIMILARITY: Contains 5 EF-hand calcium-binding domains.
CC -I- SIMILARITY: BELONGS TO PEPTIDASE FAMILY C2.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/

```

```

CC or send an email to license@isb-sib.ch).
CC EMBL; D38026; BAA07228.1; -
DR PIR; S57194; S57194.
DR HSSP; Q07009; 1DF0.
DR MEROPS; C02.002; -.
DR InterPro; IPR002048; EF-hand.
DR InterPro; IPR001300; SHprot_acsite.
DR Pfam; PF01067; Calpain_III; 1.
DR Pfam; PF00036; efhand; 3.
DR Pfam; PF00648; Peptidase_C2; 1.
DR PRINTS; PRO0704; CALPAIN.
DR SMART; SM00720; calpain_III; 1.
DR SMART; SM00230; Cyspc; 1.
DR SMART; SM00054; Eef; 3.
DR PROSITE; PS00018; EF_HAND; 2.
DR PROSITE; PS00139; THIOL_PROTEASE_CYS; 1.
DR PROSITE; PS00639; THIOL_PROTEASE_HIS; FALSE_NEG.
DR PROSITE; PS00640; THIOL_PROTEASE_ASN; FALSE_NEG.
KW Hydrolase; Thiol protease; Calcium-binding; Multigene family.
FT PROPEP 1 19 ANCHORS TO THE SMALL SUBUNIT (POTENTIAL).
FT CHAIN 20 700 CALPAIN 2, LARGE [CATALYTIC] SUBUNIT.
FT DOMAIN 20 355 CALPAIN.
FT DOMAIN 356 514 DOMAIN III.
FT DOMAIN 515 529 LINKER.
FT DOMAIN 530 700 DOMAIN IV.
FT CA_BIND 541 552 EF_HAND 1.
FT CA_BIND 585 596 EF_HAND 2.
FT CA_BIND 615 626 EF_HAND 3.
FT DOMAIN 650 661 ANCESTRAL CALCIUM SITE 4 (POTENTIAL).
FT DOMAIN 680 691 ANCESTRAL CALCIUM SITE 5 (POTENTIAL).
FT ACT_SITE 105 105 BY SIMILARITY.
FT ACT_SITE 262 262 BY SIMILARITY.
FT ACT_SITE 286 286 BY SIMILARITY.
SQ SEQUENCE 700 AA; 73228 MW; C3AEDB39CCB56D3B CRC64;

Query Match 45.5%; Score 45; DB 1; Length 700;
Best Local Similarity 57.1%; Pred. No. 33;
Matches 8; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 FEWPSYLGVEKLGFP 14
Db 52 PAGPAALGYRELGP 65

RESULT 13
SIF2_HUMAN STANDARD; PRT; 748 AA.
ID SIF2_HUMAN STANDARD; PRT; 748 AA.
AC Q9HAU4; Q9H260;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Smad ubiquitination regulatory factor 2 (EC 6.3.2.-) (Ubiquitin--
protein ligase SMURF2) (Smad-specific E3 ubiquitin ligase 2)
DE (LSMURF2).
GN SMURF2.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A., AND MUTAGENESIS OF PRO-251--VAL-284 AND
RP GLY-297--LEU-330.
RX PubMed=11163210;
RA Kaveak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H.,
RA Thomsen G.H., Wrana J.L.;
RT "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the
TGF-beta receptor for degradation."
RL Mol. Cell 6:1365-1375(2000).
RN [2]
RP SEQUENCE FROM N.A., AND MUTAGENESIS OF PRO-251--VAL-284 AND CYS-716.
RX MEDLINE=20538422; PubMed=11016919;

```

RA Lin X., Liang M., Feng X.-H.;
RT "Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent
RL degradation of Smad2 in transforming growth factor-beta signaling."
RN J. Biol. Chem. 275:36818-36822(2000).
[3]
RP SEQUENCE FROM N.A., AND MUTAGENESIS OF CYS-716.
RX MEDLINE=21107656; PubMed=11118580;
RA Zhang Y., Chang C., Gehling D.J., Hemmati-Brivanlou A., Derynck R.;
RT "Regulation of Smad degradation and activity by Smurf2, an E3
RL ubiquitin ligase."
RN Proc. Natl. Acad. Sci. U.S.A. 98:974-979(2001).
CC -!- FUNCTION: Interacts with SMAD1, SMAD2 and SMAD7 in order to
CC trigger their ubiquitination and proteasome-dependent degradation.
CC Enhances the inhibitory activity of SMAD7 and reduces the
CC transcriptional activity of SMAD2. Coexpression of SMURF2 with
CC SMAD1 results in considerable decrease in steady-state level of
CC SMAD1 protein and a smaller decrease of SMAD2 level.
CC -!- SUBUNIT: Interacts with SMAD1, SMAD2, SMAD3, SMAD6 and SMAD7 but
CC not SMAD4.
CC -!- SUBCELLULAR LOCATION: Nuclear. Cytoplasmic in the presence of
CC SMAD7.
CC -!- TISSUE SPECIFICITY: Widely expressed.
CC ;!- DOMAIN: The second and third WW domains are responsible for
CC interaction with R-SMAD (SMAD1, SMAD2 and SMAD3).
CC -!- SIMILARITY: Contains 1 C2 domain.
CC -!- SIMILARITY: Contains 3 WW domains.
CC -!- SIMILARITY: Contains 1 HECT-type E3 ubiquitin-protein ligase
CC domain.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement. (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; AF310676; AAG45422.1; -.
CC DR EMBL; AF301463; AAG25641.1; -.
CC DR EMBL; AY014180; AAG50421.1; -.
CC DR HSP; Q13526; IPIN.
CC DR MIM; 605532; -.
CC DR GO; GO:0004842; F:ubiquitin-protein ligase activity; NAS.
CC DR GO; GO:0016481; P:negative regulation of transcription; NAS.
CC DR GO; GO:0017015; P:regulation of TGFbeta receptor signaling pa...; NAS.
CC DR InterPro; IPR000008; C2.
CC DR InterPro; IPR000569; HECT domain.
CC DR InterPro; IPR001202; WW_Rsp5_WWP.
CC DR Pfam; PF00168; C2; 1.
CC DR Pfam; PF00632; HECT; 1.
CC DR Pfam; PF00397; WW; 3.
CC DR SMART; SM00239; C2; 1.
CC DR SMART; SM00119; HECT; 1.
CC DR SMART; SM00456; WW; 3.
CC DR PROSITE; PS00499; C2_DOMAIN_1; 1.
CC DR PROSITE; PS00004; C2_DOMAIN_2; 1.
CC DR PROSITE; PS02037; HECT; 1.
CC DR PROSITE; PS01159; WW_DOMAIN_1; 1.
CC DR PROSITE; PS50020; WW_DOMAIN_2; 3.
CC KW Ub1 conjugation pathway; Ligase; Repeat; Nuclear protein.
FT DOMAIN 1 98
FT DOMAIN 157 190 WW 1.
FT DOMAIN 251 284 WW 2.
FT DOMAIN 297 330 WW 3.
FT DOMAIN 414 748 HECT.
FT MUTAGEN 251 284 MISSING: ABOLISHES INTERACTION WITH
FT MUTAGEN 297 330 SMAD2 AND SMAD7.
FT MUTAGEN 297 330 MISSING: ABOLISHES INTERACTION WITH
FT MUTAGEN 716 C->A: LOSS OF ABILITY TO UBIQUITINATE
FT MUTAGEN 716 C->G: LOSS OF ACTIVITY (LOSS OF ABILITY
FT TO UBIQUITINATE SMAD1 AND SMAD2 AND NO

FT DOWN-REGULATION OF SMAD1 AND SMAD2
FT PROTEIN LEVELS).
FT G -> R (IN REF. 2).
SQ SEQUENCE 748 AA; 86195 MW; 3042B443A3755762 CRC64;

Query Match 45.5%; Score 45; DB 1; Length 748;
Best Local Similarity 53.3%; Pred. No. 35;
Matches 8; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 2 EWPSYLYGYEKLGPYY 16
II : : : : :
DB 440 EWLILLSEMLNPYY 454

RESULT 14
CB2_MALDO STANDARD; PRT; 268 AA.
AC PI5773;
DT 01-APR-1990 (Rel. 14, Created)
DT 01-APR-1990 (Rel. 14, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Chlorophyll A-B binding protein AB10, chloroplast precursor (LHCII
DE type I CAB-AB10) (LHCP).
OS Malus domestica (Apple) (Malus sylvestris).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;
OC eurosid1; Rosales; Rosaceae; Maloideae; Malus.
OX NCBI_TaxID=3730;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Golden Delicious; TISSUE=leaf;
RX MEDLINE=90175017; PubMed=2408025;
RA Chen H., Korban S.S., Buetow D.E.;
RT "Nucleotide sequence of an apple nuclear gene encoding a light-
RT harvesting chlorophyll a/b binding polypeptide of photosystem II.";
RL Nucleic Acids Res. 18:679-679(1990).
CC -!- FUNCTION: THE LIGHT-HARVESTING COMPLEX (LHC) FUNCTIONS AS A LIGHT
CC RECEPTOR, IT CAPTURES & DELIVERS EXCITATION ENERGY TO PHOTOSYSTEMS
CC WITH WHICH IT IS CLOSELY ASSOCIATED. THE N-TERMINUS OF THE PROTEIN
CC EXTENDS INTO THE STROMA WHERE IT IS INVOLVED WITH ADHESION OF
CC GRANAL MEMBRANES AND PHOTOREGULATED BY REVERSIBLE PHOSPHORYLATION
CC OF ITS THREONINE RESIDUES; BOTH ARE BELIEVED TO MEDIATE THE
CC DISTRIBUTION OF EXCITATION ENERGY BETWEEN PHOTOSYSTEMS I AND II.
CC -!- SUBUNIT: THE LHC COMPLEX CONSISTS OF CHLOROPHYLLS (A & B) AND
CC CHLOROPHYLL A-B BINDING PROTEINS.
CC -!- SUBCELLULAR LOCATION: Chloroplast thylakoid membrane.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement. (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; X17697; CAA35690.1; -.
CC DR PIR; S08229; S08229.
CC DR InterPro; IPR001344; Chloro.ABbind.
CC DR Pfam; PF00504; chloroa_b-bind; 1.
CC DR ProDom; PD000275; Chloro.ABbind; 1.
CC KW Chlorophyll; Photosynthesis; Photosystem I; Photosystem II;
KW Thylakoid; Membrane; Chloroplast; Transit peptide; Multigene family;
KW Transmembrane; Phosphorylation.
FT TRANSIT 1 40 CHLOROPLAST (PROBABLE).
FT CHAIN 41 268 CHLOROPHYLL A-B BINDING PROTEIN AB10.
FT TRANSEM 103 122 POTENTIAL.
FT TRANSEM 153 175 POTENTIAL.
FT TRANSEM 222 237 POTENTIAL.
SQ SEQUENCE 268 AA; 29211 MW; 1CAA091F7AEC6303 CRC64;

Query Match 44.4%; Score 44; DB 1; Length 268;
Best Local Similarity 64.3%; Pred. No. 18;
Matches 9; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Search completed: October 2, 2003, 14:34:09
Job time : 23 secs

QY 2 EWPSYLGKYLGPY 15
| | | | | | | | | |
DB 68 EWPSYLTGFFPGDY 81

RESULT 15

```
LEU2_PYRAE
ID LEU2_PYRAE STANDARD; PRT; 415 AA.
AC Q82W41;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE 3-isopropylmalate dehydratase large subunit (EC 4.2.1.33)
DE (Isopropylmalate isomerase) (Alpha-IPM isomerase) (IPMI).
GN LEUC OR PAE1984.
OS Pyrobaculum aerophilum.
OC Archaea; Crenarchaeota; Thermoprotei; Thermoproteales;
OC Thermoproteaceae; Pyrobaculum.
OX NCBI_TaxID=13773;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=IM2 / ATCC 51768 / DSM 7523;
RX MEDLINE=21664397; PubMed=11792869;
RA Fitz-Gibbon S.T., Ladner H., Kim U.-J., Stetter K.O., Simon M.I.,
RA Miller J.H.;
RT "Genome sequence of the hyperthermophilic crenarchaeon Pyrobaculum
RT aerophilum";
RL Proc. Natl. Acad. Sci. U.S.A. 99:984-989(2002).
CC -!- FUNCTION: Catalyzes the isomerization between 2-isopropylmalate
CC and 3-isopropylmalate, via the formation of 2-isopropylmaleate.
CC -!- CATALYTIC ACTIVITY: 3-isopropylmalate = 2-isopropylmaleate +
CC H(2)O.
CC -!- CATALYTIC ACTIVITY: 2-isopropylmaleate + H(2)O = 2-
CC isopropylmalate.
CC -!- COFACTOR: Binds 1 4Fe-4S cluster per subunit (By similarity).
CC -!- PATHWAY: Leucine biosynthesis; second step.
CC -!- SUBUNIT: Heterodimer of leuc and leud (By similarity).
CC -!- SIMILARITY: Belongs to the aconitase/IPM isomerase family. LeuC 2
CC subfamily.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AE009850; AAL63861.1; -.
CC HAMAP; MF_01027; -.
CC InterPro; IPR001030; Aconitase_N.
CC InterPro; IPR006251; Cis-H_aconitase.
CC Pfam; PF00330; aconitase; 1.
CC PRINTS; PR00415; ACONITASE.
CC ProDom; PD000511; Aconitase_N; 1.
CC TIGRfam; TIGR01343; haca_fam; 1.
CC PROSITE; PS00450; ACONITASE_1; 1.
CC PROSITE; PS01244; ACONITASE_2; FALSE_NEG.
KW Leucine biosynthesis; lyase; iron-sulfur; 4Fe-4S; complete proteome.
FT METAL 295 295 IRON-SULFUR (4FE-4S) (BY SIMILARITY).
FT METAL 353 353 IRON-SULFUR (4FE-4S) (BY SIMILARITY).
FT METAL 356 356 IRON-SULFUR (4FE-4S) (BY SIMILARITY).
SQ SEQUENCE 415 AA; 44747 MW; 2E28CA0921842473 CRC64;
```

Query Match 44.4%; Score 44; DB 1; Length 415;
Best Local Similarity 53.8%; Pred. No. 28;
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 PEWPSYLGKYLK 13
| | | | | | | | | |
DB 2 PTWTEYLKYLKLG 14

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 14:30:36 ; Search time 94 Seconds
(without alignments)
43.924 Million cell updates/sec

Title: US-09-763-848-1

Perfect score: 99

Sequence: 1 PEWPSYLGVEKLGPPY 16

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 830525 seqs, 258052604 residues

Total number of hits satisfying chosen parameters: 830525

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- 1: sp_archaea.*
- 2: sp_bacteria.*
- 3: sp_fungi.*
- 4: sp_human.*
- 5: sp_invertebrate.*
- 6: sp_mammal.*
- 7: sp_muc.*
- 8: sp_organelle.*
- 9: sp_phase.*
- 10: sp_plant.*
- 11: sp_rodent.*
- 12: sp_virus.*
- 13: sp_vertebrate.*
- 14: sp_unclassified.*
- 15: sp_virus.*
- 16: sp_bacteriap.*
- 17: sp_archaeap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	ID	Description
1	99	100.0	284	11 Q63759	Q63759 rattus norv
2	99	100.0	284	11 Q8C767	Q8C767 mus musculus
3	99	100.0	285	4 Q9H812	Q9H812 homo sapien
4	56	56.6	530	11 Q8BPV9	Q8BPV9 mus musculus
5	52	52.5	140	12 Q8JNS5	Q8JNS5 human rhino
6	52	52.5	406	10 Q43509	Q43509 lycopersico
7	51	51.5	700	6 Q9G1G1	Q9G1G1 macaca fasc
8	50	50.5	449	11 Q9ER53	Q9ER53 mus musculus
9	50	50.5	462	11 Q9ER54	Q9ER54 mus musculus
10	50	50.5	502	11 Q9ER55	Q9ER55 mus musculus
11	50	50.5	720	11 Q9ER56	Q9ER56 mus musculus
12	50	50.5	847	2 Q9ADT8	Q9ADT8 salmonella
13	49	49.5	842	5 Q9U3A8	Q9U3A8 caenorhabdi
14	49	49.5	1160	5 P90935	P90935 caenorhabdi
15	49	49.5	1286	5 P90936	P90936 caenorhabdi
16	48	48.5	466	3 O00096	O00096 talaromyces

17	47.5	48.0	273	17	O57749	O57749 pyrococcus
18	47	47.5	186	2	Q9F7D5	Q9F7D5 salmonella
19	47	47.5	218	16	Q8EB78	Q8EB78 shewanella
20	47	47.5	245	16	Q8Z6K4	Q8Z6K4 salmonella
21	47	47.5	245	16	Q944S4	Q944S4 salmonella
22	47	47.5	301	5	Q9GYC3	Q9GYC3 leishmania
23	47	47.5	456	10	Q9LX95	Q9LX95 arabidopsis
24	47	47.5	486	10	Q9FKQ1	Q9FKQ1 arabidopsis
25	47	47.5	566	5	O16200	O16200 caenorhabdi
26	47	47.5	703	11	Q64698	Q64698 rattus norv
27	46	46.5	76	2	Q8L236	Q8L236 salmonella
28	46	46.5	327	16	Q910M9	Q910M9 pseudomonas
29	46	46.5	381	11	Q91U29	Q91U29 mus musculus
30	46	46.5	469	2	Q8EGL7	Q8EGL7 streptomyce
31	46	46.5	549	17	Q8TW12	Q8TW12 methanopyru
32	46	46.5	703	11	Q91VA3	Q91VA3 mus musculus
33	45.5	46.0	361	16	Q8F776	Q8F776 leptospira
34	45.5	46.0	739	2	Q87381	Q87381 haemophilus
35	45	45.5	344	2	O66257	O66257 actinobacil
36	45	45.5	385	10	O23955	O23955 gossypium h
37	45	45.5	528	2	Q8KPV4	Q8KPV4 synechococc
38	45	45.5	551	2	Q9RH54	Q9RH54 pantoea agg
39	45	45.5	724	13	Q8UW96	Q8UW96 xenopus lae
40	45	45.5	1227	16	Q9EWF3	Q9EWF3 streptomyce
41	44.5	44.9	143	2	Q54526	Q54526 streptomyce
42	44.5	44.9	145	2	Q54808	Q54808 streptomyce
43	44.5	44.9	161	2	Q55215	Q55215 streptomyce
44	44.5	44.9	162	16	Q9BP38	Q9BP38 rhizobium l
45	44.5	44.9	177	17	Q9YAM1	Q9YAM1 aeropyrum p

ALIGNMENTS

RESULT 1

Q63759 PRELIMINARY; PRT: 284 AA.
 ID Q63759; AC Q63759; DT 01-NOV-1996 (TREMBLrel. 01, Created)
 DT 01-MAY-1999 (TREMBLrel. 10, Last sequence update)
 DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)
 DE Serine-threonine specific protein phosphatase, glycogen-binding (GL)
 DE subunit (EC 3.1.3.16).
 GN pp1R4.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=7498521;
 RA Doherty M.J., Moorhead G., Morrice N., Cohen P., Cohen P.T.;
 RT "Amino acid sequence and expression of the hepatic glycogen-binding
 (GL)-subunit of protein phosphatase-1.";
 RL FEBS Lett. 375:294-298(1995).
 RN [2]
 RC STRAIN=Sprague Dawley;
 RC MEDLINE=96085228; PubMed=74

GenCore version 5.1.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 14:32:16 ; Search time 29 seconds
(without alignments)
23.344 Million cell updates/sec

Title: US-09-763-848-1

Perfect score: 99

Sequence: 1 PEWPSYLGVEKLGPPY 16

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 328717 seqs, 42310858 residues

Total number of hits satisfying chosen parameters: 328717

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_AA.*

1: /cgn2.6/ptodata/1/iaa/5A_COMB.pep.*

2: /cgn2.6/ptodata/1/iaa/5B_COMB.pep.*

3: /cgn2.6/ptodata/1/iaa/6A_COMB.pep.*

4: /cgn2.6/ptodata/1/iaa/6B_COMB.pep.*

5: /cgn2.6/ptodata/1/iaa/PTGUS_COMB.pep.*

6: /cgn2.6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Match %	Score	Length	DB	ID	Description
1	99	100.0	284	2	US-08-767-096-3	Sequence 3, Appli
2	99	100.0	284	3	US-09-480-203-3	Sequence 3, Appli
3	56	56.6	700	4	US-09-308-345A-46	Sequence 46, Appli
4	51	51.5	700	1	US-08-726-525-7	Sequence 7, Appli
5	51	51.5	700	2	US-08-487-942-7	Sequence 7, Appli
6	51	51.5	700	2	US-08-726-036A-7	Sequence 7, Appli
7	51	51.5	700	3	US-09-422-869-23	Sequence 23, Appli
8	51	51.5	700	4	US-09-083-516-7	Sequence 7, Appli
9	48	48.5	19	3	US-08-993-165-12	Sequence 12, Appli
10	48	48.5	19	4	US-09-540-448-12	Sequence 12, Appli
11	48	48.5	19	4	US-09-243-640-10	Sequence 10, Appli
12	48	48.5	19	4	US-08-929-847-12	Sequence 12, Appli
13	48	48.5	21	3	US-08-993-165-13	Sequence 13, Appli
14	48	48.5	21	4	US-09-540-448-13	Sequence 13, Appli
15	48	48.5	21	4	US-09-243-640-11	Sequence 11, Appli
16	48	48.5	21	4	US-08-929-847-13	Sequence 13, Appli
17	48	48.5	26	6	5196510-15	Patent No. 5196510
18	48	48.5	27	6	5196510-12	Patent No. 5196510
19	48	48.5	283	4	US-09-636-499-9	Sequence 9, Appli
20	48	48.5	283	4	US-09-636-499-24	Sequence 24, Appli
21	48	48.5	450	4	US-09-044-718-9	Sequence 9, Appli
22	48	48.5	466	3	US-08-868-435-31	Sequence 31, Appli
23	48	48.5	466	4	US-08-744-231-31	Sequence 31, Appli
24	48	48.5	466	4	US-09-273-871A-13	Sequence 13, Appli
25	47	47.5	703	2	US-08-835-099A-1	Sequence 1, Appli
26	47	47.5	703	3	US-09-157-349-1	Sequence 1, Appli
27	47	47.5	703	3	US-09-422-869-27	Sequence 27, Appli

28 47 47.5 703 4 US-09-308-345A-49 Sequence 49, Appli
29 47 47.5 712 2 US-08-835-099A-2 Sequence 2, Appli
30 47 47.5 712 3 US-09-157-349-2 Sequence 2, Appli
31 46 46.5 485 4 US-09-252-991A-31436 Sequence 31436, A
32 45 45.5 735 3 US-08-539-205A-2 Sequence 2, Appli
33 45 45.5 735 4 US-09-392-163A-2 Sequence 2, Appli
34 44 44.4 168 4 US-09-328-352-4319 Sequence 4319, Ap
35 43 43.4 111 4 US-09-899-896-7 Sequence 7, Appli
36 42 42.4 123 4 US-09-247-155-103 Sequence 103, App
37 42 42.4 196 4 US-08-679-493A-185 Sequence 185, App
38 42 42.4 438 1 US-08-480-604A-23 Sequence 23, Appli
39 42 42.4 438 2 US-08-405-496A-23 Sequence 23, Appli
40 42 42.4 438 3 US-08-915-136-23 Sequence 23, Appli
41 42 42.4 462 1 US-08-480-604A-26 Sequence 26, Appli
42 42 42.4 462 2 US-08-405-496A-26 Sequence 26, Appli
43 42 42.4 462 3 US-08-915-136-26 Sequence 26, Appli
44 42 42.4 686 4 US-09-653-839-8 Sequence 8, Appli
45 42 42.4 702 4 US-09-653-839-6 Sequence 6, Appli

ALIGNMENTS

RESULT 1
US-08-767-096-3
; Sequence 3, Application US/08767096
; Patent No. 5939284
; GENERAL INFORMATION:
; APPLICANT: Cohen, Patricia T.W.
; APPLICANT: Cohen, Philip R.
; APPLICANT: Young, Peter R.
; TITLE OF INVENTION: A Protein Phosphatase 1 Binding Protein,
; TITLE OF INVENTION: R5
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SmithKline Beecham Corporation
; STREET: 709 Swedeland Road
; CITY: King of Prussia
; STATE: PA
; COUNTRY: USA
; ZIP: 19406-2799
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/767,096
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Schreck, Patricia A.
; REGISTRATION NUMBER: 33,777
; REFERENCE/DOCKET NUMBER: ATG50033
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610-270-5031
; TELEFAX: 610-270-5090
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 284 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-767-096-3

Query Match 100.0%; Score 99; DB 2; Length 284;
Best Local Similarity 100.0%; Pred. No. 1.7e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PEWPSYLGVEKLGPPY 16

Db 269 PEWPSYLGVEKLGPPY 284

RESULT 2

US-09-480-203-3
; Sequence 3, Application US/09480203
; Patent No. 6297359

GENERAL INFORMATION:
; APPLICANT: Patricia T.W. Cohen

; APPLICANT: Phillip Cohen

; APPLICANT: Peter R. Young

; TITLE OF INVENTION: A PROTEIN PHOSPHATASE 1 BINDING PROTEIN

; FILE REFERENCE: ARG-50033-2

; CURRENT APPLICATION NUMBER: US/09/480,203

; EARLIER FILING DATE: 2000-01-10

; EARLIER APPLICATION NUMBER: 09/300,327

; EARLIER FILING DATE: 1999-04-27

; EARLIER APPLICATION NUMBER: 08/767,096

; EARLIER FILING DATE: 1996-12-05

; NUMBER OF SEQ ID NOS: 6

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 3

; LENGTH: 284

; TYPE: PRT

; ORGANISM: HOMO SAPIENS

US-09-480-203-3

Query Match

Best Local Similarity 100.0%; Score 99; DB 3; Length 284;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGPPY 16

DB 269 PEWPSYLGVEKLGPPY 284

RESULT 3

US-09-308-345A-46

; Sequence 46, Application US/09308345A

; Patent No. 6569665

GENERAL INFORMATION:

; APPLICANT: BOEHM, Thomas;

; APPLICANT: DEAR, Neil T.

; TITLE OF INVENTION: No. 6569665el calpains, their preparation and use

; FILE REFERENCE: 0050/47576

; CURRENT APPLICATION NUMBER: US/09/308,345A

; CURRENT FILING DATE: 1999-05-19

; NUMBER OF SEQ ID NOS: 49

; SOFTWARE: WordPerfect v. 6.1

; SEQ ID NO 46

; LENGTH: 700

; TYPE: PRT

; ORGANISM: mouse

US-09-308-345A-46

Query Match

Best Local Similarity 56.6%; Score 56; DB 4; Length 700;

Matches 10; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGPPY 15

DB 52 PALPSSSLGVEKLGPPY 66

RESULT 4

US-08-726-525-7

; Sequence 7, Application US/08726525

; Patent No. 5789181

GENERAL INFORMATION:

; APPLICANT: Lin, Lih-Ling

; APPLICANT: Graham, James

; TITLE OF INVENTION: NOVEL INTERLEUKIN-1 RECEPTOR

; TITLE OF INVENTION: INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND

; TITLE OF INVENTION: BINDING

; NUMBER OF SEQUENCES: 7

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: LEGAL AFFAIRS, GENETICS INSTITUTE, INC.

; STREET: 87 Cambridgepark Drive

; CITY: Cambridge

; STATE: MA

; COUNTRY: USA

; ZIP: 02140

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/726,525

; FILING DATE: 07-OCT-1996

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/487,942

; FILING DATE: 07-JUN-1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Brown, Scott A.

; REGISTRATION NUMBER: 32,724

; REFERENCE/DOCKET NUMBER: GI5258

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 498-8224

; TELEFAX: (617) 876-5851

; INFORMATION FOR SEQ ID NO: 7:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 700 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: protein

; HYPOTHETICAL: NO

US-08-726-525-7

Query Match

Best Local Similarity 51.5%; Score 51; DB 1; Length 700;

Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGPPY 15

DB 52 PAIPSSSLGVEKLGPPY 66

RESULT 5

US-08-487-942-7

; Sequence 7, Application US/08487942

; Patent No. 5817476

GENERAL INFORMATION:

; APPLICANT: Lin, Lih-Ling

; APPLICANT: Graham, James

; TITLE OF INVENTION: NOVEL INTERLEUKIN-1 RECEPTOR

; TITLE OF INVENTION: INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND

; NUMBER OF SEQUENCES: 7

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: LEGAL AFFAIRS, GENETICS INSTITUTE, INC.

; STREET: 87 Cambridgepark Drive

; CITY: Cambridge

; STATE: MA

; COUNTRY: USA

; ZIP: 02140

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/487,942

; FILING DATE:

```

; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15258
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 700 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; US-08-487-942-7

```

```

Query Match 51.5%; Score 51; DB 2; Length 700;
Best Local Similarity 60.0%; Pred. No. 8;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 1 PEPMSYLVGYKELGYPY 15
   | |||:::||||
Db 52 PAIPSAFGKELGYPY 66

```

RESULT 6

```

US-08-726-036A-7
; Sequence 7, Application US/08726036A
; Patent No. 5981482

```

GENERAL INFORMATION:

```

; APPLICANT: Lin, Lih-Ling
; APPLICANT: Graham, James
; TITLE OF INVENTION: NOVEL INTERLEUKIN-1 RECEPTOR
; TITLE OF INVENTION: INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND
; TITLE OF INVENTION: BINDING
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LEGAL AFFAIRS, GENETICS INSTITUTE, INC.
; STREET: 87 Bridgepark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140

```

COMPUTER READABLE FORM:

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/726,036A
; FILING DATE:
; CLASSIFICATION: 435

```

ATTORNEY/AGENT INFORMATION:

```

; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15258
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 700 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; US-08-726-036A-7

```

```

Query Match 51.5%; Score 51; DB 2; Length 700;
Best Local Similarity 60.0%; Pred. No. 8;

```

```

Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
QY 1 PEPMSYLVGYKELGYPY 15
   | |||:::||||
Db 52 PAIPSAFGKELGYPY 66

```

RESULT 7

```

US-09-422-869-23
; Sequence 23, Application US/09422869
; Patent No. 6235481

```

GENERAL INFORMATION:

```

; APPLICANT: POLONSKI, KENNETH S.
; APPLICANT: HORIKAWA, YUKIO
; APPLICANT: ODA, NAOHISA
; APPLICANT: COX, NANCY J.
; APPLICANT: SREENAN, SEAMUS
; APPLICANT: ZHOU, YUN-PING
; APPLICANT: OTANI, KENICHI
; APPLICANT: HANIS, CRAIG L.
; APPLICANT: BELL, GRAEME I.
; TITLE OF INVENTION: METHODS OF TREATMENT OF TYPE 2 DIABETES
; FILE REFERENCE: ARCD:307
; CURRENT APPLICATION NUMBER: US/09/422,869
; CURRENT FILING DATE: 1999-10-21
; EARLIER APPLICATION NUMBER: 60/134,175
; EARLIER FILING DATE: 1999-05-13
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 23
; LENGTH: 700
; TYPE: PRT
; ORGANISM: Human
; US-09-422-869-23

```

Query Match

```

51.5%; Score 51; DB 3; Length 700;
Best Local Similarity 60.0%; Pred. No. 8;

```

Matches

```

9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
QY 1 PEPMSYLVGYKELGYPY 15
   | |||:::||||
Db 52 PAIPSAFGKELGYPY 66

```

RESULT 8

```

US-09-083-516-7
; Sequence 7, Application US/09083516
; Patent No. 6300086

```

GENERAL INFORMATION:

```

; APPLICANT: Lin, Lih-Ling
; APPLICANT: Graham, James
; TITLE OF INVENTION: NOVEL INTERLEUKIN-1 RECEPTOR
; TITLE OF INVENTION: INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND
; TITLE OF INVENTION: BINDING
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LEGAL AFFAIRS, GENETICS INSTITUTE, INC.
; STREET: 87 Bridgepark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/083,516
; FILING DATE:
; CLASSIFICATION:

```

ATTORNEY/AGENT INFORMATION:

```

; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15258
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 700 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; US-08-726-036A-7

```

```

Query Match 51.5%; Score 51; DB 3; Length 700;
Best Local Similarity 60.0%; Pred. No. 8;

```

Matches

```

9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
QY 1 PEPMSYLVGYKELGYPY 15
   | |||:::||||
Db 52 PAIPSAFGKELGYPY 66

```

```
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A. 32,724
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: G15258
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 700 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
US-09-083-516-7

Query Match 51.5%; Score 51; DB 4; Length 700;
Best Local Similarity 60.0%; Pred. No. 8;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEPSPYLYGKELGPYY 15
DB 52 PAIPSAIGKELGPYY 66

RESULT 9
US-08-993-165-12
; Sequence 12, Application US/08993165A
; Patent No. 6123923
; GENERAL INFORMATION:
; APPLICANT: Unger, Evan C
; APPLICANT: Wu, Yunqiu
; TITLE OF INVENTION: Optoacoustic Contrast Agents And Methods For Their Use
; FILE REFERENCE: UNGR1224
; CURRENT APPLICATION NUMBER: US/08/993,165A
; CURRENT FILING DATE: 1997-12-18
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6123923el Sequence
US-08-993-165-12

Query Match 48.5%; Score 48; DB 3; Length 19;
Best Local Similarity 61.5%; Pred. No. 0.51;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 4 PSYLYGKELGPYY 16
DB 3 PSYRYDGAGPYY 15

RESULT 10
US-09-540-448-12
; Sequence 12, Application US/09540448
; Patent No. 6403056
; GENERAL INFORMATION:
; APPLICANT: Unger, Evan C.
; TITLE OF INVENTION: Charged Lipids and Uses For The Same
; FILE REFERENCE: UNGR1592
; CURRENT APPLICATION NUMBER: US/09/540,448
; CURRENT FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 08/925,353
; PRIOR FILING DATE: 1997-09-08
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 19
```

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6403056el Sequence
US-09-540-448-12

Query Match 48.5%; Score 48; DB 4; Length 19;
Best Local Similarity 61.5%; Pred. No. 0.51;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 4 PSYLYGKELGPYY 16
DB 3 PSYRYDGAGPYY 15

RESULT 11
US-09-243-640-10
; Sequence 10, Application US/09243640
; Patent No. 6521211
; GENERAL INFORMATION:
; APPLICANT: Unger, Evan C
; APPLICANT: Shen, Dekang
; APPLICANT: Wu, Guanli
; TITLE OF INVENTION: No. 6521211el Methods Of Imaging And Treatment With Targeted
; FILE REFERENCE: DUP-0463
; CURRENT APPLICATION NUMBER: US/09/243,640
; CURRENT FILING DATE: 1999-02-03
; PRIOR APPLICATION NUMBER: 08/660,032
; PRIOR FILING DATE: 1996-06-06
; PRIOR APPLICATION NUMBER: 08/640,464
; PRIOR FILING DATE: 1996-05-01
; PRIOR APPLICATION NUMBER: 08/497,684
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 09/218,660
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/073,913
; PRIOR FILING DATE: 1998-02-06
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6521211el Sequence
US-09-243-640-10

Query Match 48.5%; Score 48; DB 4; Length 19;
Best Local Similarity 61.5%; Pred. No. 0.51;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 4 PSYLYGKELGPYY 16
DB 3 PSYRYDGAGPYY 15

RESULT 12
US-08-929-847-12
; Sequence 12, Application US/08929847
; Patent No. 6548047
; GENERAL INFORMATION:
; APPLICANT: Unger, Evan C.
; TITLE OF INVENTION: Thermal Preactivation Of Gaseous Precursor Filled Compositions
; FILE REFERENCE: BMS0441
; CURRENT APPLICATION NUMBER: US/08/929,847
; CURRENT FILING DATE: 1997-09-15
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Completely synthetic sequence
US-08-929-847-12

Query Match      48.5%; Score 48; DB 4; Length 19;
Best Local Similarity 61.5%; Pred. No. 0.51;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      4 PSYLYEKLGPYY 16
      ||| | : ||||
Db      3 PSYRYDAGPYY 15

RESULT 13
US-08-993-165-13
; Sequence 13, Application US/08993165A
; Patent No. 6123923
; GENERAL INFORMATION:
; APPLICANT: Unger, Evan C
; APPLICANT: Wu, Yunqiu
; TITLE OF INVENTION: Optoacoustic Contrast Agents And Methods For Their Use
; FILE REFERENCE: UNGR1224
; CURRENT APPLICATION NUMBER: US/08/993,165A
; CURRENT FILING DATE: 1997-12-18
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6123923el Sequence
US-08-993-165-13

Query Match      48.5%; Score 48; DB 3; Length 21;
Best Local Similarity 61.5%; Pred. No. 0.56;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      4 PSYLYEKLGPYY 16
      ||| | : ||||
Db      5 PSYRYDAGPYY 17

RESULT 14
US-09-540-448-13
; Sequence 13, Application US/09540448
; Patent No. 6403056
; GENERAL INFORMATION:
; APPLICANT: Unger, Evan C.
; TITLE OF INVENTION: Charged Lipids and Uses For The Same
; FILE REFERENCE: UNGR1592
; CURRENT APPLICATION NUMBER: US/09/540,448
; CURRENT FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: 08/925,353
; PRIOR FILING DATE: 1997-09-08
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6403056el Sequence
US-09-540-448-13

Query Match      48.5%; Score 48; DB 4; Length 21;
Best Local Similarity 61.5%; Pred. No. 0.56;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      4 PSYLYEKLGPYY 16
      ||| | : ||||
Db      5 PSYRYDAGPYY 17
```

```
RESULT 15
US-09-243-640-11
; Sequence 11, Application US/09243640
; Patent No. 6521211
; GENERAL INFORMATION:
; APPLICANT: Unger, Evan C
; APPLICANT: Shen, Dekang
; APPLICANT: Wu, Guanli
; TITLE OF INVENTION: No. 6521211el Methods Of Imaging And Treatment With Targeted
; TITLE OF INVENTION: Compositions
; FILE REFERENCE: DCP-0463
; CURRENT APPLICATION NUMBER: US/09/243,640
; CURRENT FILING DATE: 1999-02-03
; PRIOR APPLICATION NUMBER: 08/660,032
; PRIOR FILING DATE: 1996-06-06
; PRIOR APPLICATION NUMBER: 08/640,464
; PRIOR FILING DATE: 1996-05-01
; PRIOR APPLICATION NUMBER: 08/497,684
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 09/218,660
; PRIOR FILING DATE: 1998-12-22
; PRIOR APPLICATION NUMBER: 60/073,913
; PRIOR FILING DATE: 1998-02-06
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6521211el Sequence
US-09-243-640-11

Query Match      48.5%; Score 48; DB 4; Length 21;
Best Local Similarity 61.5%; Pred. No. 0.56;
Matches 8; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy      4 PSYLYEKLGPYY 16
      ||| | : ||||
Db      5 PSYRYDAGPYY 17
```

Search completed: October 2, 2003, 14:37:14
Job time : 30 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 14:36:01 ; Search time 66 Seconds
(without alignments)
38.355 Million cell updates/sec

Title: US-09-763-848-1
Perfect score: 99
Sequence: 1 PEWPSYLGVEKLGPPY 16

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 587654 seqs, 158212981 residues

Total number of hits satisfying chosen parameters: 587654

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications_AA:*

- 1: /cgn2_6/ptodata/2/pubaa/US07_PUBCOMB.pep:*
- 2: /cgn2_6/ptodata/2/pubaa/PCT_NEW_PUB.pep:*
- 3: /cgn2_6/ptodata/2/pubaa/US06_NEW_PUB.pep:*
- 4: /cgn2_6/ptodata/2/pubaa/US06_PUBCOMB.pep:*
- 5: /cgn2_6/ptodata/2/pubaa/US07_NEW_PUB.pep:*
- 6: /cgn2_6/ptodata/2/pubaa/PCTUS_PUBCOMB.pep:*
- 7: /cgn2_6/ptodata/2/pubaa/US08_NEW_PUB.pep:*
- 8: /cgn2_6/ptodata/2/pubaa/US08_PUBCOMB.pep:*
- 9: /cgn2_6/ptodata/2/pubaa/US09A_PUBCOMB.pep:*
- 10: /cgn2_6/ptodata/2/pubaa/US09B_PUBCOMB.pep:*
- 11: /cgn2_6/ptodata/2/pubaa/US09C_PUBCOMB.pep:*
- 12: /cgn2_6/ptodata/2/pubaa/US09_NEW_PUB.pep:*
- 13: /cgn2_6/ptodata/2/pubaa/US10A_PUBCOMB.pep:*
- 14: /cgn2_6/ptodata/2/pubaa/US10B_PUBCOMB.pep:*
- 15: /cgn2_6/ptodata/2/pubaa/US10C_PUBCOMB.pep:*
- 16: /cgn2_6/ptodata/2/pubaa/US10_NEW_PUB.pep:*
- 17: /cgn2_6/ptodata/2/pubaa/US60_NEW_PUB.pep:*
- 18: /cgn2_6/ptodata/2/pubaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	99	100.0	282	9	US-09-737-149-43
2	99	100.0	284	9	US-09-737-149-42
3	99	100.0	285	9	US-09-737-149-12
4	53	53.5	545	15	US-10-156-761-9468
5	51	51.5	700	9	US-09-840-707A-9
6	51	51.5	700	10	US-09-768-877-23
7	51	51.5	700	11	US-09-884-319-7
8	51	51.5	700	15	US-10-038-557A-9
9	51	51.5	700	15	US-10-116-519-12
10	48	48.5	19	15	US-10-046-801-12
11	48	48.5	21	15	US-10-046-801-13
12	48	48.5	283	15	US-10-229-358-9
13	48	48.5	283	15	US-10-229-358-24
14	48	48.5	450	15	US-10-062-848-9
15	48	48.5	466	14	US-10-083-452-13

16	47	47.5	647	15	US-10-116-519-10	Sequence 10, Appl
17	47	47.5	703	10	US-09-768-877-27	Sequence 27, Appl
18	46	46.5	469	12	US-10-314-657-71	Sequence 71, Appl
19	45	45.5	278	15	US-10-156-761-15067	Sequence 15067, A
20	45	45.5	385	10	US-09-837-751-4	Sequence 4, Appl
21	45	45.5	748	12	US-10-021-660-81	Sequence 81, Appl
22	44	44.4	255	15	US-10-224-446-30	Sequence 30, Appl
23	44	44.4	255	15	US-10-287-401-30	Sequence 30, Appl
24	43	43.4	111	9	US-09-899-896-7	Sequence 7, Appl
25	43	43.4	253	11	US-09-880-748-1835	Sequence 1835, Ap
26	43	43.4	300	9	US-09-794-960-5	Sequence 5, Appl
27	42	42.4	123	12	US-09-903-190-103	Sequence 103, App
28	42	42.4	343	9	US-09-794-960-4	Sequence 4, Appl
29	42	42.4	383	9	US-09-852-399-4	Sequence 4, Appl
30	42	42.4	399	15	US-10-224-446-4	Sequence 4, Appl
31	42	42.4	399	15	US-10-287-401-4	Sequence 4, Appl
32	42	42.4	414	12	US-10-097-111-290	Sequence 290, App
33	42	42.4	425	9	US-09-288-326-9	Sequence 9, Appl
34	42	42.4	434	11	US-09-910-186A-4	Sequence 4, Appl
35	42	42.4	435	11	US-09-910-186A-6	Sequence 6, Appl
36	42	42.4	437	11	US-09-910-186A-2	Sequence 2, Appl
37	42	42.4	702	15	US-10-116-519-11	Sequence 11, Appl
38	42	42.4	714	10	US-09-768-877-22	Sequence 22, Appl
39	42	42.4	714	15	US-10-116-519-6	Sequence 6, Appl
40	42	42.4	1295	10	US-10-097-534-14	Sequence 14, Appl
41	42	42.4	1295	10	US-09-726-949A-1	Sequence 1, Appl
42	41.5	41.9	152	9	US-09-815-242-13962	Sequence 13962, A
43	41	41.4	1246	9	US-09-741-669-349	Sequence 349, App
44	41	41.4	1247	9	US-09-815-242-10145	Sequence 10145, A
45	41	41.4	1247	9	US-09-815-242-13841	Sequence 13841, A

ALIGNMENTS

RESULT 1

US-09-737-149-43
; Sequence 43, Application US/09737149
; Patent No. US20020077466A1
; GENERAL INFORMATION:
; APPLICANT: Spaderna, Steven K
; APPLICANT: Quinn, Kerry E.
; APPLICANT: Shinkets, Richard A.
; APPLICANT: Muralidhara, Padigaru
; APPLICANT: Spytek, Kimberly A.
; TITLE OF INVENTION: Polypeptides and Nucleic Acids Encoding Same
; FILE REFERENCE: 15966-620 CIP
; CURRENT APPLICATION NUMBER: US/09/737,149
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/170,564
; PRIOR FILING DATE: 1999-12-14
; PRIOR APPLICATION NUMBER: 60/173,165
; PRIOR FILING DATE: 1999-12-27
; PRIOR APPLICATION NUMBER: 60/173,362
; PRIOR FILING DATE: 1999-12-27
; PRIOR APPLICATION NUMBER: 60/173,544
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 60/174,404
; PRIOR FILING DATE: 2000-01-04
; PRIOR APPLICATION NUMBER: 60/174,962
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: 60/223,929
; PRIOR FILING DATE: 2000-08-09
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43
; LENGTH: 282
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Consensus Sequence
; NAME/KEY: VARIANT
; LOCATION: (1)..(282)

; OTHER INFORMATION: Where X is a residue at which the query and
; OTHER INFORMATION: subject sequences are not identical.
US-09-737-149-43

Query Match 100.0%; Score 99; DB 9; Length 282;
Best Local Similarity 100.0%; Pred. No. 3.4e-07; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGPPY 16
| | | | | | | | | | | | | | | | | |
Db 267 PEWPSYLGVEKLGPPY 282

RESULT 2
US-09-737-149-42
; Sequence 42, Application US/09737149
; Patent No. US2002007466A1
; GENERAL INFORMATION:
; APPLICANT: Spaderna, Steven K
; APPLICANT: Quinn, Kerry E.
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Muralidhara, Padigaru
; APPLICANT: Spytek, Kimberly A.
; TITLE OF INVENTION: Polypeptides and Nucleic Acids Encoding Same
; FILE REFERENCE: 15966-620 CIP
; CURRENT APPLICATION NUMBER: US/09/737,149
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/170,564
; PRIOR FILING DATE: 1999-12-14
; PRIOR APPLICATION NUMBER: 60/173,165
; PRIOR FILING DATE: 1999-12-27
; PRIOR APPLICATION NUMBER: 60/173,362
; PRIOR FILING DATE: 1999-12-27
; PRIOR APPLICATION NUMBER: 60/173,544
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 60/174,404
; PRIOR FILING DATE: 2000-01-04
; PRIOR APPLICATION NUMBER: 60/174,962
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: 60/223,929
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 42
; LENGTH: 284
; TYPE: PRT
; ORGANISM: Rattus norvegicus

US-09-737-149-42

Query Match 100.0%; Score 99; DB 9; Length 284;
Best Local Similarity 100.0%; Pred. No. 3.5e-07; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGPPY 16
| | | | | | | | | | | | | | | | | |
Db 269 PEWPSYLGVEKLGPPY 284

RESULT 3
US-09-737-149-42
; Sequence 12, Application US/09737149
; Patent No. US2002007466A1
; GENERAL INFORMATION:
; APPLICANT: Spaderna, Steven K
; APPLICANT: Quinn, Kerry E.
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Muralidhara, Padigaru
; APPLICANT: Spytek, Kimberly A.
; TITLE OF INVENTION: Polypeptides and Nucleic Acids Encoding Same
; FILE REFERENCE: 15966-620 CIP
; CURRENT APPLICATION NUMBER: US/09/737,149
; CURRENT FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/170,564

; PRIOR FILING DATE: 1999-12-14
; PRIOR APPLICATION NUMBER: 60/173,165
; PRIOR FILING DATE: 1999-12-27
; PRIOR APPLICATION NUMBER: 60/173,362
; PRIOR FILING DATE: 1999-12-27
; PRIOR APPLICATION NUMBER: 60/173,544
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 60/174,404
; PRIOR FILING DATE: 2000-01-04
; PRIOR APPLICATION NUMBER: 60/174,962
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: 60/223,929
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 12
; LENGTH: 285
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-737-149-12

Query Match 100.0%; Score 99; DB 9; Length 285;
Best Local Similarity 100.0%; Pred. No. 3.5e-07;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLGPPY 16
| | | | | | | | | | | | | | | | | |
Db 270 PEWPSYLGVEKLGPPY 285

RESULT 4
US-10-156-761-9468
; Sequence 9468, Application US/10156761
; Publication No. US20030119018A1
; GENERAL INFORMATION:
; APPLICANT: OMURA, SATOSHI
; APPLICANT: IKEDA, HARUO
; APPLICANT: ISHIKAWA, JUN
; APPLICANT: HORIKAWA, HIROSHI
; APPLICANT: SHIBA, TADAYOSHI
; APPLICANT: SAKAKI, YOSHIYUKI
; APPLICANT: HATTORI, MASAHIRO
; TITLE OF INVENTION: NOVEL POLYNUCLEOTIDES
; FILE REFERENCE: 249-262
; CURRENT APPLICATION NUMBER: US/10/156,761
; CURRENT FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: JP 2001-204089
; PRIOR FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: JP 2001-272697
; PRIOR FILING DATE: 2001-08-02
; NUMBER OF SEQ ID NOS: 15109
; SEQ ID NO 9468
; LENGTH: 545
; TYPE: PRT
; ORGANISM: Streptomyces avermitilis
US-10-156-761-9468

Query Match 53.5%; Score 53; DB 15; Length 545;
Best Local Similarity 62.5%; Pred. No. 5.4;
Matches 10; Conservative 1; Mismatches 3; Indels 2; Gaps 1;

QY 1 PEWPSYLGVEKLGPPY 16
| | | | | | | | | | | | | | | | | |
Db 128 PAMP--LSYELEPPY 141

RESULT 5
US-09-840-707A-9
; Sequence 9, Application US/09840707A
; Patent No. US20020077276A1
; GENERAL INFORMATION:
; APPLICANT: Fredeking, Terry M.
; APPLICANT: Ignatyev, George M.

;; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS
;; FILE REFERENCE: 24881-301C
;; CURRENT APPLICATION NUMBER: US/09/840,707A
;; CURRENT FILING DATE: 2001-04-23
;; PRIOR APPLICATION NUMBER: 09/562,979
;; PRIOR FILING DATE: 2000-04-27
;; PRIOR APPLICATION NUMBER: 60/198,210
;; PRIOR FILING DATE: 1999-04-27
;; NUMBER OF SEQ ID NOS: 26
;; SOFTWARE: PatentIn Ver. 2.0
;; SEQ ID NO 9
;; LENGTH: 700
;; TYPE: PRT
;; ORGANISM: Homo sapiens
;; FEATURE:
;; OTHER INFORMATION: IL-1 receptor intracellular ligand protein
;; OTHER INFORMATION: comprising amino acid sequence
;; PUBLICATION INFORMATION:
;; PATENT DOCUMENT NUMBER: 5,817,476
;; PATENT FILING DATE: 1995-06-07
;; PUBLICATION DATE: 1998-10-06
US-09-840-707A-9

Query Match 51.5%; Score 51; DB 9; Length 700;
Best Local Similarity 60.0%; Pred. No. 14;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKELGPY 15
| |||:::||||
Db 52 PAIPSAFGFKELGPY 66

RESULT 6

US-09-768-877-23
; Sequence 23, Application US/09768877
; Patent No. US20020150896A1
; GENERAL INFORMATION:
; APPLICANT: POLONSKY, KENNETH S.
; APPLICANT: HORIKAWA, YUKIO
; APPLICANT: ODA, NAOHISA
; APPLICANT: COX, NANCY J.
; APPLICANT: SEENAN, SEAMUS
; APPLICANT: ZHOU, XUN-PING
; APPLICANT: OTANI, KENICHI
; APPLICANT: HANIS, CRAIG L.
; APPLICANT: BELL, GRAEME I.
; TITLE OF INVENTION: METHODS OF TREATMENT OF TYPE 2 DIABETES
; FILE REFERENCE: ARCD:307
; CURRENT APPLICATION NUMBER: US/09/768,877
; CURRENT FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 09/422,869
; PRIOR FILING DATE: 1999-10-21
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 23
; LENGTH: 700
; TYPE: PRT
; ORGANISM: Human
US-09-768-877-23

Query Match 51.5%; Score 51; DB 10; Length 700;
Best Local Similarity 60.0%; Pred. No. 14;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKELGPY 15
| |||:::||||
Db 52 PAIPSAFGFKELGPY 66

RESULT 7

US-09-884-319-7
; Sequence 7, Application US/09884319

;; Publication No. US20030124625A1
;; GENERAL INFORMATION:
;; APPLICANT: Lin, Lih-Ling
;; APPLICANT: Graham, James
;; TITLE OF INVENTION: NOVEL INTERLEUKIN-1 RECEPTOR
;; INTRACELLULAR LIGAND PROTEINS AND INHIBITORS OF LIGAND
;; BINDING
;; NUMBER OF SEQUENCES: 7
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: LEGAL AFFAIRS, GENETICS INSTITUTE, INC.
;; STREET: 87 CambridgePark Drive
;; CITY: Cambridge
;; STATE: MA
;; COUNTRY: USA
;; ZIP: 02140
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/884,319
;; FILING DATE: 18-Jun-2001
;; CLASSIFICATION: <Unknown>
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/09/083,516
;; FILING DATE: <Unknown>
;; APPLICATION NUMBER: 08/487,942
;; FILING DATE: <Unknown>
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Brown, Scott A.
;; REGISTRATION NUMBER: 32,724
;; REFERENCE/DOCKET NUMBER: GI5258
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (617) 498-8224
;; TELEFAX: (617) 876-5851
;; INFORMATION FOR SEQ ID NO: 7:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 700 amino acids
;; TYPE: amino acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: protein
;; HYPOTHEetical: NO
;; SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-884-319-7

Query Match 51.5%; Score 51; DB 11; Length 700;
Best Local Similarity 60.0%; Pred. No. 14;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKELGPY 15
| |||:::||||
Db 52 PAIPSAFGFKELGPY 66

RESULT 8

US-10-038-557A-9
; Sequence 9, Application US/10038557A
; Publication No. US20030092684A1
; GENERAL INFORMATION:
; APPLICANT: Fredeking, Terry M.
; APPLICANT: Ignatyev, George M.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS
; FILE REFERENCE: 24881-301D
; CURRENT APPLICATION NUMBER: US/10/038,557A
; CURRENT FILING DATE: 2002-06-05
; PRIOR APPLICATION NUMBER: 09/840,707
; PRIOR FILING DATE: 2001-04-23
; PRIOR APPLICATION NUMBER: 09/562,979
; PRIOR FILING DATE: 2000-04-27
; PRIOR APPLICATION NUMBER: 60/198,210

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 2, 2003, 14:23:05 ; Search time 82 Seconds
(without alignments)
30.971 Million cell updates/sec

Title: US-09-763-848-1
Perfect score: 99
Sequence: 1 PEWPSYLGVEKLGPPY 16

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

```

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
                  Maximum Match 10%
                  Listing first 45

```

```

Database :
A_Geneseq_19Jun03.*
1: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1980.DAT.*
2: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1981.DAT.*
3: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1982.DAT.*
4: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1983.DAT.*
5: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1984.DAT.*
6: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1985.DAT.*
7: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1986.DAT.*
8: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1987.DAT.*
9: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1988.DAT.*
10: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1989.DAT.*
11: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1990.DAT.*
12: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1991.DAT.*
13: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1992.DAT.*
14: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1993.DAT.*
15: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1994.DAT.*
16: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1995.DAT.*
17: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1996.DAT.*
18: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1997.DAT.*
19: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1998.DAT.*
20: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA1999.DAT.*
21: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA2000.DAT.*
22: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA2001.DAT.*
23: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA2002.DAT.*
24: /SIDSL/cgcdata/geneseq/genesexp-emb1/AA2003.DAT.*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query %			DB ID	Description
		Match	Length			
1	99	100.0	284	23	AAE14236	Human protein phos
2	99	100.0	285	22	AAU02201	Phosphatase 1 prot
3	99	100.0	285	22	AAK95633	Human protein sequ
4	90	90.9	15	21	ABV79064	C-terminal peptide
5	52	52.5	700	22	ABG6130	Rat calpain 80kDa
6	51	51.5	144	22	AAU33305	Novel human enzyme
7	51	51.5	700	18	AAW19992	Human CAMP used to
8	51	51.5	700	21	AB37797	Human interleukin-
9	51	51.5	700	22	AB86128	Human calpain 80kD

10	51	51.5	700	23	AAE25059	Human calpain prot
11	50	50.5	447	23	AAAM49720	Murine capn12 prot
12	50	50.5	462	23	AAAM49719	Murine calpain pro
13	50	50.5	518	23	AAAM49718	Murine calpain pro
14	50	50.5	720	23	AAAM49717	Murine calpain pro
15	48.5	49.0	82	23	ABP107099	Human ORFX protein
16	48	48.5	19	18	AAW45497	Targeting ligand d
17	48	48.5	19	21	AAAB205095	Glycoprotein GPIIb
18	48	48.5	19	23	ABG303088	Glycoprotein GPIIb
19	48	48.5	21	18	AAW45498	Targeting ligand d
20	48	48.5	21	21	AAAB205096	Glycoprotein GPIIb
21	48	48.5	21	23	ABG303089	Glycoprotein GPIIb
22	48	48.5	26	12	AAAR15276	Anti-thrombic fusi
23	48	48.5	27	12	AAAR15273	Anti-thrombic fusi
24	48	48.5	127	11	AAAR06335	Peptide correspond
25	48	48.5	219	15	AAAR56235	h66-118/h13-65/11-
26	48	48.5	233	15	AAAR56236	h66-111/112-65/11-
27	48	48.5	283	22	AAAB71730	P.piceum phytase p
28	48	48.5	283	22	AAAB71733	P.piceum phytase p
29	48	48.5	443	21	AAAB20512	Talaromyces thermo
30	48	48.5	443	21	AAAY69555	Talaromyces thermo
31	48	48.5	466	19	AAW843355	Talaromyces thermo
32	48	48.5	466	20	AAV398399	T. thermophilus ph
33	47	47.5	300	22	AAAM39363	Human polypeptide
34	47	47.5	352	21	AAAG47099	Arabidopsis thalia
35	47	47.5	399	22	AAAM41149	Human polypeptide
36	47	47.5	429	21	AAAG47098	Arabidopsis thalia
37	47	47.5	486	21	AAAG47097	Arabidopsis thalia
38	47	47.5	703	18	AAW41564	Human calpain. Ho
39	47	47.5	703	23	AAE134338	Human protease prt
40	47	47.5	703	23	AAUT2888A	Human aspartyl pro
41	47	47.5	712	18	AAW41565	Human calpain. Ho
42	46	46.5	306	24	ABR41522	Human b1rHP protei
43	46	46.5	467	23	AAE25058	Human calpain prot
44	46	46.5	469	24	ABU11410	Protein encoded by
45	46	46.5	648	23	ABG70268	Human Calpain-like

ALIGNMENTS

RESULT 1
AAE14236
ID AAE14236 standard: Protein: 284 AA:

XX	07-MAR-2002 (first entry)
DT	
XX	
DE	Human protein phosphatase-1 (pp-1).

KW Human; protein phosphatase-1, pp1; gene therapy; tranquillisers; amnesia;
KW arteriosclerosis; atherosclerosis; anxiety; anaemia; hepatitis; cataract;
KW atrophic lateral sclerosis; adenocarcinoma; cerebral palsy; psoriasis;
KW ulcerative colitis; myxantha gravis; infection; schizophrenia disorder;
KW neurological disorder; epilepsy; neoplasm; Alzheimer's disease; dementia;
KW thyroiditis; dermatitis; diabetic mellitus; rheumatoid arthritis; stroke;
KW granulomatous disease; haemolytic anaemia; Crohn's disease; cancer; SCID;
KW severe combined immunodeficiency disease; immune system disorder; trauma;
KW developmental disorder; cell proliferative disease; Addison's disease;
KW systemic lupus erythematosus; parkinson's disease; myelofibrosis; AIDS;
KW leukaemia; antiflammatory; cirrhosis; muscular dystrophy; allergy.

XX	
OS	Homo sapiens.
XX	
XX	
PN	WC200181590-A2.
XX	
XX	
ED	01-NOV-2001.
XX	
XX	
PF	19-APR-2001; 2001WO-TSL2902.
XX	
XX	
PR	20-APR-2000; 2000US-199010P.
PR	05-WAY-2000; 2000US-202340P.

PR 10-MAY-2000; 2000US-203424P.
 PR 18-MAY-2000; 2000US-205642P.
 PR 02-JUN-2000; 2000US-208954P.
 XX
 PA (INCY-) INCYTE GENOMICS INC.
 XX
 PI Tang YT, Yue H, Khan FA, Wang YE, Patterson C, Gandhi AR;
 PI Wallia NK, Stewart EA, Tribouley CM, Hafalia A, Nguyen DB;
 PI Elliott VS, Lee BA;
 XX
 DR WPI; 2002-034445/04.
 DR N-PSDB; RAD23604.
 XX
 PT Novel polypeptides for diagnosing, preventing, treating immune system,
 PT neurological, developmental and cell proliferative disorders including
 PT cancer, comprises protein phosphatase polypeptides and encoding
 PT polynucleotides -
 XX
 PS Claim 1; Page 97-98; 105pp; English.
 XX
 CC The invention relates to human protein phosphatases (PP-1 to PP-5) and
 CC their corresponding DNA molecules. Protein phosphatases and their DNA's
 CC are useful for diagnosis, treatment and prevention of immune system
 CC disorders (AIDS, severe combined immunodeficiency disease (SCID), chronic
 CC granulomatous disease, autoimmune haemolytic anaemia, Crohn's disease,
 CC autoimmune thyroiditis, atopic dermatitis, diabetic mellitus, rheumatoid
 CC arthritis, systemic lupus erythematosus, systemic sclerosis, Addison's
 CC disease, ulcerative colitis, haemodialysis ureitis, myasthenia gravis,
 CC trauma, viral, bacterial, fungal, parasitic, protozoal and helminthic
 CC infections); neurological disorders (epilepsy, stroke, cerebral neoplasm,
 CC Alzheimer's disease, Huntington's disease, Parkinson's disease,
 CC amyotrophic lateral sclerosis, dementia, prion diseases); developmental
 CC disorders (Down syndrome, cerebral palsy, spinal cord diseases, amnesia,
 CC autonomic nervous system disorders, muscular dystrophy, anxiety anaemia,
 CC schizophrenic disorders, diabetic neuropathy, Tourette's disorder,
 CC cataract, sensorineural hearing loss); cell proliferative disorders
 CC (bursitis, arteriosclerosis, atherosclerosis, cirrhosis, hepatitis,
 CC myelofibrosis, psoriasis, cancers including adenocarcinoma, leukaemia,
 CC lymphoma, melanoma, myeloma, sarcoma and cancers of the bone, brain,
 CC breast, ovary, bladder, heart, kidney, liver, and pancreas. Protein
 CC phosphatases, its fragments and its antibodies are useful as elements on
 CC a micro array which is useful to monitor or measure protein-protein
 CC interactions, drug-target interactions and gene expression profiles.
 CC The present sequence is human protein phosphatase-1 (PP-1).
 XX
 SQ Sequence 284 AA;
 Query Match 100.0%; Score 99; DB 23; Length 284;
 Best Local Similarity 100.0%; Pred. No. 6.5e-07;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 PEWPSYLGVEKLGPTY 16
 | | | | | | | | | | | | | | | | | |
 Db 269 PEWPSYLGVEKLGPTY 284
 RESULT 2
 AAU02201
 ID AAU02201 standard; Protein; 285 AA.
 XX
 AC AAU02201;
 XX
 DT 26-SEP-2001 (first entry)
 XX
 DE Phosphatase 1 protein-like protein, MEM6.
 XX
 KW Phosphatase 1; MEM1; therapeutic; diagnostic; MEM2;
 KW human; Alzheimer's disease; Parkinson's disease; cancer; nephrology;
 KW female reproductive health; lung disorder; brain disorder; schizophrenia;
 KW heart disorder; arrhythmia; muscular disorder; clotting deficiency; MEM3;
 KW cobalamin deficiency; pernicious anaemia; diabetes; MEM4; MEM5; MEM6;
 KW vision-related disorder; neoplastic pathology; MEM7; MEM8.
 XX

OS Homo sapiens.
 XX
 PN WO200144473-A2.
 XX
 PD 21-JUN-2001.
 XX
 PF 14-DEC-2000; 2000WO-US33909.
 XX
 PR 14-DEC-1999; 99US-0170564.
 PR 27-DEC-1999; 99US-0173165.
 PR 27-DEC-1999; 99US-0173362.
 PR 29-DEC-1999; 99US-0173544.
 PR 04-JAN-2000; 2000US-9966564.
 PR 03-AUG-2000; 2000US-0223929.
 PR 13-DEC-2000; 2000US-9966565.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Spaderna SK, Quinn KE, Shinkets RA, Muralidhara P, Spytek KA;
 XX
 DR WPI; 2001-398154/42.
 DR N-PSDB; AAS06337.
 XX
 PT Novel polypeptide comprising members of protein families (e.g.,
 PT seven-pass transmembrane receptor proteins) according to presence of
 PT domains and sequence relatedness are useful for treating or preventing,
 PT e.g., Alzheimer's and Parkinson's -
 PS Claim 1; Fig 27; 162pp; English.
 XX
 CC The sequence represents the amino acid sequence of phosphatase 1
 CC protein-like protein, MEM6, selected from a group (MEM1-MEM8) comprising
 CC members of protein families according to the presence of domains and
 CC sequence relatedness, e.g., seven-pass transmembrane receptor protein
 CC (MEM1), glutamate receptor (MEM2-MEM4), potassium channel receptor protein
 CC phosphatase 1 protein (MEM6), and retinol-binding protein (MEM7-MEM8).
 CC The MEM polypeptides (I), nucleic acids (II), and antibodies (III) are
 CC all useful for treating or preventing a pathology associated with (I)
 CC comprising administering (I), (II), or (III) to a subject (preferably a
 CC human). In addition, (I), (II), and (III) may be used to manufacture a
 CC medicament for treating a syndrome associated with a human disease that
 CC is associated with (I). Furthermore, (I) may be used to identify agents
 CC that bind to (I), screen modulators of its activity and determine the
 CC presence or predisposition to a disease associated with altered levels of
 CC (I). Disorders for MEM1 include Alzheimer's or Parkinson's Disease,
 CC cancer, nephrology, and female reproductive health. Disorders for MEM4
 CC include those involving the lung and/or brain (e.g., schizophrenia). For
 CC MEM5, disorders include heart (arrhythmic disorders) and other muscular
 CC disorders, clotting deficiencies and cobalamin deficiencies (e.g.,
 CC pernicious anaemia). Such disorders for MEM6 include diabetes, whereas
 CC disorders for MEM7 and MEM8 include vision-related disorders, cancer,
 CC and other neoplastic pathologies.
 XX
 SQ Sequence 285 AA;
 Query Match 100.0%; Score 99; DB 22; Length 285;
 Best Local Similarity 100.0%; Pred. No. 6.6e-07;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 PEWPSYLGVEKLGPTY 16
 | | | | | | | | | | | | | | | | | |
 Db 270 PEWPSYLGVEKLGPTY 285
 RESULT 3
 AAB95633
 ID AAB95633 standard; Protein; 285 AA.
 XX
 AC AAB95633;
 XX
 DT 26-JUN-2001 (first entry)
 XX
 DE Human protein sequence SEQ ID NO:18363.

XX Human; primer; detection; diagnosis; antisense therapy; gene therapy.
 XX Homo sapiens.
 XX EP1074617-A2.
 XX 07-FEB-2001.
 XX 28-JUL-2000; 2000EP-0116126.
 XX 29-JUL-1999; 99JP-0248036.
 XX 27-AUG-1999; 99JP-0300253.
 XX 11-JAN-2000; 2000JP-0118776.
 XX 02-MAY-2000; 2000JP-0183767.
 XX 09-JUN-2000; 2000JP-0241899.
 XX (HELI-) HELIX RES INST.
 XX Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
 XX Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
 XX WPI; 2001-318749/34.
 XX Primer sets for synthesizing polynucleotides, particularly the 5602
 XX full-length cDNAs defined in the specification, and for the detection
 XX and/or diagnosis of the abnormality of the proteins encoded by the
 XX full-length cDNAs -
 XX Claim 8; SEQ ID 18363; 2537pp + CD ROM; English.
 XX The present invention describes primer sets for synthesizing 5602
 XX full-length cDNAs defined in the specification. Where a primer set
 XX comprises: (a) an oligo-dn primer and an oligonucleotide complementary
 XX to the complementary strand of a polynucleotide which comprises one of
 XX the 5602 nucleotide sequences defined in the specification, where the
 XX oligonucleotide comprises at least 15 nucleotides; or (b) a combination
 XX of an oligonucleotide comprising a sequence complementary to the
 XX complementary strand of a polynucleotide which comprises a 5'-end
 XX sequence and an oligonucleotide comprising a sequence complementary to a
 XX polynucleotide which comprises a 3'-end sequence, where the
 XX oligonucleotide comprises at least 15 nucleotides and the combination of
 XX the 5'-end sequence/3'-end sequence is selected from those defined in
 XX the specification. The primer sets can be used in antisense therapy and
 XX in gene therapy. The primers are useful for synthesizing polynucleotides,
 XX particularly full-length cDNAs. The primers are also useful for the
 XX detection and/or diagnosis of the abnormality of the proteins encoded by
 XX the full-length cDNAs. The primers allow obtaining of the full-length
 XX cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
 XX AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
 XX AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
 XX represent oligonucleotides, all of which are used in the exemplification
 XX of the present invention.
 XX SQ Sequence 285 AA;
 XX Query Match 100.0%; Score 99; DB 22; Length 285;
 XX Best Local Similarity 100.0%; Pred. No. 6.6e-07;
 XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX Qy 1 PEWPSYLGYEKLGPPY 16
 XX |||||||||||||
 XX Db 270 PEWPSYLGYEKLGPPY 285
 XX RESULT 4
 XX AAY79064
 XX ID AAY79064 standard; peptide; 16 AA.
 XX AC AAY79064;
 XX 12-JUN-2000 (first entry)
 XX

DE C-terminal peptide of rat liver PPI GL subunit.
 XX Protein phosphatase 1; ppi; glycogen targeting subunit; blood glucose;
 KW phosphorylase alpha; glycogen synthesis; hyperglycaemic disorder; GL;
 KW type I diabetes; type II diabetes.
 XX Rattus sp.
 XX WO200012549-A1.
 XX 09-MAR-2000.
 XX 19-AUG-1999; 99WO-GB02761.
 XX 27-AUG-1998; 98GB-0018650.
 XX (MEDI-) MEDICAL RES COUNCIL.
 XX Cohen PTW, Armstrong CG, Doherty MJ;
 XX WPI; 2000-256587/22.
 XX Lowering blood sugar levels in the treatment of diabetes, using a
 XX compound that blocks interaction between phosphorylase alpha and
 XX protein phosphatase 1 glycogen-targeting subunit -
 XX Claim 4; Page 35; 51pp; English.
 XX This sequence represents the C-terminal amino acid sequence of the rat
 XX liver protein phosphatase 1 (PPI) glycogen targeting subunit (GL). The
 XX invention relates to the medicinal use of a compound capable of blocking
 XX the interaction of phosphorylase alpha with GL, where the compound
 XX comprises the present peptide sequence or a fragment of it. When
 XX phosphatase alpha binds to GL it potentially inhibits its glycogen
 XX synthase phosphatase activity and inhibits glycogen synthesis, this
 XX contributes to high blood glucose levels. The invention also relates to
 XX a method for identifying the compound. The compound can be used to reduce
 XX the blood glucose level of a mammal, particularly a human, in
 XX hyperglycaemic disorders such as type I or type II diabetes.
 XX SQ Sequence 16 AA;
 XX Query Match 90.9%; Score 90; DB 21; Length 16;
 XX Best Local Similarity 93.8%; Pred. No. 6.8e-07;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX Qy 1 PEWPSYLGYEKLGPPY 16
 XX |||||||||||||
 XX Db 1 PEWPSYLGYEKLGPPY 16
 XX RESULT 5
 XX AAB86130
 XX ID AAB86130 standard; protein; 700 AA.
 XX AC AAB86130;
 XX 27-JUL-2001 (first entry)
 XX Rat calpain 80kDa subdomain protein fragment.
 XX Calpain; calcium-activated cysteine proteinase; human; spatial structure;
 KW Ca-activated cysteine proteinase; protein coordinate data; treatment;
 KW structure-function study; ischemic condition; muscular dystrophy; tumor;
 KW muscular; antitumor.
 XX Rattus norvegicus.
 XX EF1108779-A2.
 XX 20-JUN-2001.
 XX 13-DEC-2000; 2000EP-0127369.
 XX

```

XX 14-DEC-1999; 99DE-1060225.
XX (PIAC ) MAX PLANCK GRS FOERDERUNG WISSENSCHAFTEN.
PA (PROT-) PROTEROS BIOSTRUCTURES GMBH.
XX Strobl S, Fernandez-Catalan C, Bode W, Huber R, Suzuki K;
XX WPI; 2001-376928/40.
XX Spatial structures containing calpain-derived polypeptides, useful for
PT identifying calpain modulators and substrates, potentially useful e.g.
PT as antitumor agents
XX Claim 15; Fig 6; 182pp; German.
XX This invention describes the novel spatial structure of human and rat
CC neutral calcium-activated cysteine protease (calpain) family. The spatial
CC structure (especially crystalline forms) are used for structure-function
CC studies, particularly for identifying (pseudo)substrates, inhibitors and
CC activators of calpains, potentially useful for treatment of ischemic
CC conditions, muscular dystrophy and/or tumors. The products of the
CC invention have anti-ischemic, muscular and antitumor activity. This
CC sequence represents the rat calpain 80kDa subunit described in the
CC method of the invention.
XX
XX Sequence 700 AA;
SQ
Query Match 52.5%; Score 52; DB 22; Length 700;
Best Local Similarity 60.0%; Pred. No. 21;
Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 PEMPSYGLYKERIGPY 15
Db 52 PALPSSIGPKELGPy 66

RESULT 6
AAU23305
ID AAU23305 standard; Protein; 144 AA.
XX
AC AAU23305;
XX
DT 17-DEC-2001 (first entry)
XX
DE Novel human enzyme polypeptide #391.
XX
KW Human; oxidoreductase enzyme; transferase; hydrolase; lyase; isomerase;
KW ligase; hyperproliferative disorder; immunodeficiency disorder;
KW autoimmune disorder; neurological disorder; metabolic disorder;
KW inflammatory disorder; cardiovascular disorder; reproductive disorder;
KW blood-related disorder; infectious disorder; cytostatic; anti arthritic;
KW nephrotropic; anticoagulant.
XX
OS Homo sapiens.
XX
XX WO200155301-A2.
XX
PD 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US01239.
XX
XX 31-JAN-2000; 2000US-0179065.
XX 04-FEB-2000; 2000US-0180628.
XX 24-FEB-2000; 2000US-0184664.
XX 02-MAR-2000; 2000US-0186350.
XX 16-MAR-2000; 2000US-0189874.
XX 17-MAR-2000; 2000US-0190076.
XX 18-APR-2000; 2000US-0198123.
XX 19-MAY-2000; 2000US-0205515.
XX 07-JUN-2000; 2000US-0209467.
XX 28-JUN-2000; 2000US-0214886.
XX 30-JUN-2000; 2000US-0215135.
XX
07-JUL-2000; 2000US-0216647.
PR
07-JUL-2000; 2000US-0216880.
PR
11-JUL-2000; 2000US-0217487.
PR
11-JUL-2000; 2000US-0217496.
PR
14-JUL-2000; 2000US-0218290.
PR
26-JUL-2000; 2000US-0220963.
PR
26-JUL-2000; 2000US-0220964.
PR
14-AUG-2000; 2000US-0224518.
PR
14-AUG-2000; 2000US-0224519.
PR
14-AUG-2000; 2000US-0225213.
PR
14-AUG-2000; 2000US-0225214.
PR
14-AUG-2000; 2000US-0225266.
PR
14-AUG-2000; 2000US-0225267.
PR
14-AUG-2000; 2000US-0225268.
PR
14-AUG-2000; 2000US-0225270.
PR
14-AUG-2000; 2000US-0225447.
PR
14-AUG-2000; 2000US-0225757.
PR
14-AUG-2000; 2000US-0225758.
PR
18-AUG-2000; 2000US-0225759.
PR
18-AUG-2000; 2000US-0226279.
PR
22-AUG-2000; 2000US-0226681.
PR
22-AUG-2000; 2000US-0226868.
PR
22-AUG-2000; 2000US-0227182.
PR
23-AUG-2000; 2000US-0227009.
PR
30-AUG-2000; 2000US-0228924.
PR
01-SEP-2000; 2000US-0229287.
PR
01-SEP-2000; 2000US-0229343.
PR
01-SEP-2000; 2000US-0229344.
PR
05-SEP-2000; 2000US-0229345.
PR
05-SEP-2000; 2000US-0229509.
PR
05-SEP-2000; 2000US-0229513.
PR
06-SEP-2000; 2000US-0230437.
PR
06-SEP-2000; 2000US-0230438.
PR
08-SEP-2000; 2000US-0231242.
PR
08-SEP-2000; 2000US-0231243.
PR
08-SEP-2000; 2000US-0231244.
PR
08-SEP-2000; 2000US-0231413.
PR
08-SEP-2000; 2000US-0231414.
PR
08-SEP-2000; 2000US-0232080.
PR
08-SEP-2000; 2000US-0232081.
PR
12-SEP-2000; 2000US-0231968.
PR
14-SEP-2000; 2000US-0232397.
PR
14-SEP-2000; 2000US-0232398.
PR
14-SEP-2000; 2000US-0232399.
PR
14-SEP-2000; 2000US-0232400.
PR
14-SEP-2000; 2000US-0232401.
PR
14-SEP-2000; 2000US-0233063.
PR
14-SEP-2000; 2000US-0233064.
PR
14-SEP-2000; 2000US-0233065.
PR
21-SEP-2000; 2000US-0234223.
PR
21-SEP-2000; 2000US-0234274.
PR
25-SEP-2000; 2000US-0234997.
PR
25-SEP-2000; 2000US-0234998.
PR
26-SEP-2000; 2000US-0235484.
PR
27-SEP-2000; 2000US-0235834.
PR
27-SEP-2000; 2000US-0235836.
PR
29-SEP-2000; 2000US-0236327.
PR
29-SEP-2000; 2000US-0236367.
PR
29-SEP-2000; 2000US-0236368.
PR
29-SEP-2000; 2000US-0236369.
PR
29-SEP-2000; 2000US-0236370.
PR
02-OCT-2000; 2000US-0236802.
PR
02-OCT-2000; 2000US-0237037.
PR
02-OCT-2000; 2000US-0237038.
PR
02-OCT-2000; 2000US-0237039.
PR
02-OCT-2000; 2000US-0237040.
PR
13-OCT-2000; 2000US-0239935.
PR
13-OCT-2000; 2000US-0239937.
PR
20-OCT-2000; 2000US-0240960.
PR
20-OCT-2000; 2000US-0241221.
PR
20-OCT-2000; 2000US-0241785.
PR
20-OCT-2000; 2000US-0241786.
PR
20-OCT-2000; 2000US-0241787.

```

PR 20-OCT-2000; 2000US-0241808.
 PR 20-OCT-2000; 2000US-0241809.
 PR 20-OCT-2000; 2000US-0241826.
 PR 01-NOV-2000; 2000US-0244617.
 PR 08-NOV-2000; 2000US-0246474.
 PR 08-NOV-2000; 2000US-0246475.
 PR 08-NOV-2000; 2000US-0246476.
 PR 08-NOV-2000; 2000US-0246477.
 PR 08-NOV-2000; 2000US-0246478.
 PR 08-NOV-2000; 2000US-0246523.
 PR 08-NOV-2000; 2000US-0246524.
 PR 08-NOV-2000; 2000US-0246525.
 PR 08-NOV-2000; 2000US-0246526.
 PR 08-NOV-2000; 2000US-0246527.
 PR 08-NOV-2000; 2000US-0246528.
 PR 08-NOV-2000; 2000US-0246532.
 PR 08-NOV-2000; 2000US-0246609.
 PR 08-NOV-2000; 2000US-0246610.
 PR 08-NOV-2000; 2000US-0246611.
 PR 08-NOV-2000; 2000US-0246613.
 PR 17-NOV-2000; 2000US-0249207.
 PR 17-NOV-2000; 2000US-0249208.
 PR 17-NOV-2000; 2000US-0249209.
 PR 17-NOV-2000; 2000US-0249210.
 PR 17-NOV-2000; 2000US-0249211.
 PR 17-NOV-2000; 2000US-0249212.
 PR 17-NOV-2000; 2000US-0249213.
 PR 17-NOV-2000; 2000US-0249214.
 PR 17-NOV-2000; 2000US-0249215.
 PR 17-NOV-2000; 2000US-0249216.
 PR 17-NOV-2000; 2000US-0249217.
 PR 17-NOV-2000; 2000US-0249218.
 PR 17-NOV-2000; 2000US-0249244.
 PR 17-NOV-2000; 2000US-0249245.
 PR 17-NOV-2000; 2000US-0249264.
 PR 17-NOV-2000; 2000US-0249265.
 PR 17-NOV-2000; 2000US-0249267.
 PR 17-NOV-2000; 2000US-0249297.
 PR 17-NOV-2000; 2000US-0249299.
 PR 01-DEC-2000; 2000US-0249300.
 PR 01-DEC-2000; 2000US-0250160.
 PR 01-DEC-2000; 2000US-0250391.
 PR 05-DEC-2000; 2000US-0251030.
 PR 05-DEC-2000; 2000US-0251988.
 PR 05-DEC-2000; 2000US-0256719.
 PR 06-DEC-2000; 2000US-0251479.
 PR 08-DEC-2000; 2000US-0251856.
 PR 08-DEC-2000; 2000US-0251868.
 PR 08-DEC-2000; 2000US-0251869.
 PR 08-DEC-2000; 2000US-0251989.
 PR 08-DEC-2000; 2000US-0251990.
 PR 11-DEC-2000; 2000US-0254097.
 PR 03-JAN-2001; 2001US-0259678.
 PR (HUMA-) HUMAN GENOME SCI INC.
 XX PA
 XX Rosen CA, Barash SC, Ruben SK;
 XX WPI; 2001-465566/50.
 DR N-PSDB; AAS41175.
 XX

Novel polypeptides and polynucleotides useful for diagnosing,
 preventing, treating neural, immune system, muscular, reproductive,
 pulmonary, cardiovascular, renal, proliferative disorders and cancerous
 diseases -

Claim 11; SEQ ID No 1301; 1180pp; English.

CC The present invention relates to the isolation of novel human enzyme
 CC polypeptides, and the cDNA (AAS40785-AAS41684) and genomic sequences
 CC encoding them. The enzyme polypeptides of the invention may comprise the
 CC functional classes of oxidoreductases, transferases, hydrolases, lyases,
 CC isomerases or ligases. The sequences of the invention are useful in the
 CC diagnosis, treatment, prevention and/or prognosis of a wide range of

CC disorders including hyperproliferative disorders (e.g. cancer),
 CC immunodeficiency disorders (e.g. AIDS) autoimmune disorders
 CC (e.g. arthritis), neurological disorders (e.g. Alzheimer's disease),
 CC metabolic disorders (e.g. phenylketonuria), inflammatory disorders
 CC (e.g. asthma), cardiovascular disorders (e.g. atherosclerosis),
 CC blood-related disorders (e.g. haemophilia), reproductive disorders
 CC (e.g. infertility) and infectious disorders (e.g. influenza). The
 CC polynucleotides of the invention can also be used in gene therapy.
 CC AAN22915-AAU23814 represent the novel human enzyme polypeptides of the
 CC invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.
 XX

XX Sequence 144 AA;

Query Match 51.5%; Score 51; DB 22; Length 144;

Best Local Similarity 60.0%; Pred. NO. 5.5; Mismatches 3; Indels 0; Gaps 0;
 Matches 9; Conservative 3;

QY 1 PEWPSYIGYKLGYPY 15
 | | | | | | | | | |
 Db 81 PAIPSAIGKELGYPY 95

RESULT 7

AAW19992

ID AAW19992 standard; Protein; 700 AA.

XX AC AAW19992;

XX DT 27-AUG-1997 (first entry)

XX Human CAMP used to identify inhibitors of interleukin-1 activity.

DE IL; interleukin; receptor; ligand; screening assay; inhibitor;
 KW IL-1 mediated response; inflammation; inflammatory; antibody;
 KW intracellular domain; CAMP; calcium activated neutral protease.

XX Homo sapiens.

XX WO9640907-A1.

XX 19-DEC-1996.

XX 06-MAY-1996; 96WO-US06363.

XX 07-JUN-1995; 95US-0487942.

XX (GENY) GENETICS INST INC.

XX Graham J, Lin L;

XX WPI; 1997-052315/05.

XX Interleukin-1 receptor intracellular ligand proteins and related DNA
 XX - used to identify inhibitors of the proteins for treatment of
 XX inflammation

XX Claim 14; Page 36-38; 54pp; English.

XX AAW19992 represents human calcium activated neutral protease (CAMP).
 CC This protein was found to have an area of high homology with an
 CC interleukin-1 receptor (IL-1-R) intracellular ligand (encoded by cDNA
 CC clone 14w, see AAW1218) and thus will display some of the same
 CC properties of this protein. IL-1-R intracellular ligand proteins are
 CC used to screen for agents (e.g. antibodies) that are capable of
 CC inhibiting or blocking the binding of an IL-1-R intracellular ligand
 CC to the intracellular domain of IL-1-R, i.e. inhibitors of IL-1
 CC activity. Such agents can be used to treat inflammatory conditions.
 XX Sequence 700 AA;

Query Match 51.5%; Score 51; DB 18; Length 700;
Best Local Similarity 60.0%; Pred. No. 30;
Matches 9; Conservative 3; Mismatches 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15
DB 52 PAIPSAFGKELGYPY 66

RESULT 8

AAE37797
ID AAB37797 standard; Protein; 700 AA.
AC AAB37797;
XX
XX 23-FEB-2001 (first entry)
XX
XX Human interleukin-1 receptor intracellular ligand protein #4.
DE
XX Human; interleukin-1; IL-1; IL-1alpha; IL-1beta; IL-1 receptor;
KW antiinflammatory; haemostatic; antibacterial; immunosuppressive;
KW immunomodulator; cardiatic; cytostatic; neuroprotective; respiratory;
KW inflammation; infection; sepsis; cachexia; autoimmune disorder;
KW cardiovascular disorder; chronic myelogenous leukaemia;
KW multiple sclerosis; inflammatory bowel disease; Crohn's disease.
XX
XX Homo sapiens.
XX WO200064479-A1.
XX
XX 02-NOV-2000.
XX
XX 26-APR-2000; 2000WO-US11700.
XX
XX 27-APR-1999; 99US-0301274.
XX
XX (ANTI-) ANTIBODY SYSTEMS INC.
XX
XX Fredeking TM, Ignatyev GM;
XX
XX WPL; 2000-679646/66.
XX
XX Novel compositions comprising tetracycline or tetracycline-like
XX compounds for the treatment and/or prevention of acute inflammatory
XX responses and diseases, e.g. septic shock and immune complex-induced
XX colitis -
XX
XX Disclosure; Page 159-162; 183pp; English.

XX The present sequence is given in a specification relating to novel
XX compositions and methods containing tetracycline or tetracycline-like
XX compounds for treating and/or preventing acute inflammatory responses and
XX diseases. Such diseases include acute inflammatory conditions associated
XX with viral haemorrhagic diseases (including diseases caused by
XX Parvoviridae, Filoviridae, Flaviviridae or Arenaviridae viruses);
XX parasitic diseases, bacterial infections, sepsis, cachexia, autoimmune
XX disorders, acute cardiovascular events, chronic myelogenous leukaemia and
XX transplanted bone marrow-induced graft-versus-host disease, septic shock,
XX immune complex-induced colitis, cerebrospinal fluid inflammation,
XX multiple sclerosis, inflammatory responses associated with trauma,
XX systemic inflammatory response syndrome (SIRS), adult respiratory
XX distress syndrome (ARDS), acute liver failure, inflammatory bowel disease
XX and Crohn's disease.
XX
XX Sequence 700 AA;

Query Match 51.5%; Score 51; DB 21; Length 700;
Best Local Similarity 60.0%; Pred. No. 30;
Matches 9; Conservative 3; Mismatches 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15
DB 52 PAIPSAFGKELGYPY 66

RESULT 9
AAB86128
ID AAB86128 standard; protein; 700 AA.
XX
XX AAB86128;
XX
XX 27-JUL-2001 (first entry)
XX
XX Human calpain 80kDa subdomain protein fragment.

XX
XX Calpain; calcium-activated cysteine proteinase; human; spatial structure;
KW Ca-activated cysteine proteinase; protein coordinate data; treatment;
KW structure-function study; ischemic condition; muscular dystrophy; tumor;
KW muscular; antitumor.
XX
XX Homo sapiens.
XX
XX RE1108779-A2.
XX
XX 20-JUN-2001.
XX
XX 13-DEC-2000; 2000EP-0127369.
XX
XX 14-DEC-1999; 99DE-1060225.
XX
XX (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.
XX (PROT-) PROTEROS BIOSTRUCTURES GMBH.
XX
XX Strobl S, Fernandez-Catalan C, Bode W, Huber R, Suzuki K;
XX
XX WPI; 2001-376928/40.

XX Spatial structures containing calpain-derived polypeptides, useful for
XX identifying calpain modulators and substrates, potentially useful e.g.
XX as antitumor agents -
XX
XX Claim 15; Fig 4; 182pp; German.

XX This invention describes the novel spatial structure of human and rat
XX neutral calcium-activated cysteine protease (calpain) family. The spatial
XX structure (especially crystalline forms) are used for structure-function
XX studies, particularly for identifying (pseudo)substrates, inhibitors and
XX activators of calpains, potentially useful for treatment of ischemic
XX conditions, muscular dystrophy and/or tumors. The products of the
XX invention have anti-ischemic, muscular and antitumor activity. This
XX sequence represents the human calpain 80kDa subunit described in the
XX method of the invention.
XX
XX Sequence 700 AA;

Query Match 51.5%; Score 51; DB 22; Length 700;
Best Local Similarity 60.0%; Pred. No. 30;
Matches 9; Conservative 3; Mismatches 0; Gaps 0;

QY 1 PEWPSYLGVEKLGYPY 15
DB 52 PAIPSAFGKELGYPY 66

RESULT 10
AAE25059
ID AAE25059 standard; Protein; 700 AA.
XX
XX AAE25059;
XX
XX 30-OCT-2002 (first entry)
XX
XX Human calpain protein #2.
XX
XX Human; calpain; nervous system disorder; amyotrophic lateral sclerosis;
KW Parkinson's disease; dementia; genito-urinary system disorder; stroke;

KW Alzheimer's disease; multiple sclerosis; benign prostate hyperplasia;
 KW urinary incontinence; gene therapy; cytostatic; nootropic; uropathic;
 KW neuroprotective.
 XX Homo sapiens.
 OS WO200248326-A2.
 XX 20-JUN-2002.
 XX 14-DEC-2001; 2001WO-EP14819.
 XX 14-DEC-2000; 2000US-255038P.
 XX (FARB) BAYER AG.
 XX Ramakrishnan S;
 FI WPI; 2002-537625/57.
 XX New human calpain polypeptide, useful for treating peripheral and
 PT central nervous system disorder and genito-urinary system disorders
 PT including urinary incontinence and benign prostate hyperplasia -
 XX Disclosure; Page 101-104; 110pp; English.
 XX The invention relates to novel human calpain proteins and polynucleotides
 CC encoding such proteins. Calpain sequences of the invention are useful for
 CC treating, ameliorating or correcting dysfunctions or diseases such as
 CC peripheral or central nervous system (CNS) disorders (e.g., Parkinson's
 CC disease, Alzheimer's disease, multiple sclerosis, stroke, amyotrophic
 CC lateral sclerosis, dementia) and genito-urinary system disorders such
 CC as urinary incontinence and benign prostate hyperplasia. They are also
 CC used in gene therapy. The present sequence is human calpain protein.
 XX
 XX Sequence 700 AA;
 SQ
 Query Match 51.5%; Score 51; DB 23; Length 700;
 Best Local Similarity 60.0%; Pred. NO. 30;
 Matches 9; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
 QY - 1 PEWPSYLGVEKLGPP 15
 Db | ||| ||| : ||| |||
 52 PAIPSAFGFKELGPP 66
 RESULT 11
 AAM49720
 ID AAM49720 standard; Protein; 447 AA.
 XX
 AC AAM49720;
 XX 11-JUN-2002 (first entry)
 DT Murine capn12 protein.
 DE Calpain protease; capn12; splice variant; murine; gene therapy;
 XX screening; diagnosis.
 KW Mus sp.
 XX DE10031932-A1.
 XX 10-JAN-2002.
 XX 30-JUN-2000; 2000DE-1031932.
 XX 30-JUN-2000; 2000DE-1031932.
 XX (BADI) BASF AG.
 XX Not given;
 XX This invention describes a novel murine calpain protease 12 (capn12).
 CC The calpain protease of the invention, related proteins and nucleic acid
 CC that encodes it, are useful for treatment (including gene therapy) of
 CC diseases associated with insufficient expression of the calpain protease.
 CC The protein is also used to screen for calpain protein effectors and to
 CC raise specific immunoglobulins (Ig) useful for diagnosis. Also the
 CC polynucleotide encoding capn12 is useful, e.g. as primers and probes, for
 CC diagnosis of diseases, or predisposition to them, and for recombinant
 CC production of capn12. This sequence represents the calpain protease
 CC capn12 protein described in the disclosure of the invention.

DR WPI; 2002-115441/16.
 DR N-PSDB; ABA99771.
 XX New calpain protein 12 with cysteine protease activity, useful for
 PT treating specific deficiency disorders -
 XX Claim 2; Page 18-20; 36pp; German.
 XX This invention describes a novel murine calpain protease 12 (capn12).
 CC The calpain protease of the invention, related proteins and nucleic acid
 CC that encodes it, are useful for treatment (including gene therapy) of
 CC diseases associated with insufficient expression of the calpain protease.
 CC The protein is also used to screen for calpain protein effectors and to
 CC raise specific immunoglobulins (Ig) useful for diagnosis. Also the
 CC polynucleotide encoding capn12 is useful, e.g. as primers and probes, for
 CC diagnosis of diseases, or predisposition to them, and for recombinant
 CC production of capn12. This sequence represents the calpain protease
 CC capn12 protein described in the disclosure of the invention.
 XX
 XX Sequence 447 AA;
 SQ
 Query Match 50.5%; Score 50; DB 23; Length 447;
 Best Local Similarity 64.3%; Pred. No. 26;
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;
 QY 1 PEWPSYLGVEKLGPP 14
 Db | | | ||| |||
 52 PAGDPALGYDKLGPP 65
 RESULT 12
 AAM49719
 ID AAM49719 standard; Protein; 462 AA.
 XX
 AC AAM49719;
 XX 11-JUN-2002 (first entry)
 DT Murine calpain protease 12 variant capn12C.
 DE Calpain protease; capn12; splice variant; murine; gene therapy;
 XX screening; diagnosis; capn12C.
 KW Mus sp.
 XX DE10031932-A1.
 XX 10-JAN-2002.
 XX 30-JUN-2000; 2000DE-1031932.
 XX 30-JUN-2000; 2000DE-1031932.
 XX (BADI) BASF AG.
 XX Not given;
 XX WPI; 2002-115441/16.
 DR N-PSDB; ABA99770.
 XX New calpain protein 12 with cysteine protease activity, useful for
 PT treating specific deficiency disorders -
 XX Claim 2; Page 17-18; 36pp; German.
 XX This invention describes a novel murine calpain protease 12 (capn12).
 CC The calpain protease of the invention, related proteins and nucleic acid
 CC that encodes it, are useful for treatment (including gene therapy) of
 CC diseases associated with insufficient expression of the calpain protease.
 CC The protein is also used to screen for calpain protein effectors and to
 CC raise specific immunoglobulins (Ig) useful for diagnosis. Also the
 CC polynucleotide encoding capn12 is useful, e.g. as primers and probes, for
 CC diagnosis of diseases, or predisposition to them, and for recombinant

CC production of capn12. This sequence represents the calpain protease
 CC splice variant capn12C described in the disclosure of the invention.

XX
 SQ Sequence 462 AA;

Query Match 50.5%; Score 50; DB 23; Length 462;
 Best Local Similarity 64.3%; Pred. No. 27;
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLG 14
 | | | | | | | | | |
 Db 52 PAGPDALGYDKLGP 65

RESULT 13

AM49718
 ID AAM49718 standard; Protein; 518 AA.

XX AC
 XX AC AAM49718;

XX DT
 XX DT 11-JUN-2002 (first entry)

DE Murine calpain protease 12 variant capn12B.

XX Calpain protease; capn12; splice variant; murine; gene therapy;
 KW screening; diagnosis; capn12B.

XX OS
 XX OS Mus sp.

XX PH Key Location/Qualifiers

XX FT Misc-difference 493..510

XX FT /note= "Encoded by GGTGGT"

XX PN DE10031932-AL.

XX PD 10-JAN-2002.

XX PF 30-JUN-2000; 2000DE-1031932.

XX PR 30-JUN-2000; 2000DE-1031932.

XX PA (BADI) BASF AG.

XX PI Not given;

XX DR WPI; 2002-115441/16.

XX DR N-PSDB; ABA99769.

XX PT New calpain protein 12 with cysteine protease activity, useful for
 PT treating specific deficiency disorders -

XX PS Claim 2; Page 15-17; 36pp; German.

XX CC This invention describes a novel murine calpain protease 12 (capn12).
 CC The calpain protease of the invention, related proteins and nucleic acid
 CC that encodes it, are useful for treatment (including gene therapy) of
 CC diseases associated with insufficient expression of the calpain protease.
 CC The protein is also used to screen for calpain protein effectors and to
 CC raise specific immunoglobulins (Ig) useful for diagnosis. Also the
 CC polynucleotide encoding capn12 is useful, e.g. as primers and probes, for
 CC diagnosis of diseases, or predisposition to them, and for recombinant
 CC production of capn12. This sequence represents the calpain protease
 CC splice variant capn12B described in the disclosure of the invention.

XX SQ Sequence 518 AA;

Query Match 50.5%; Score 50; DB 23; Length 518;
 Best Local Similarity 64.3%; Pred. No. 31;
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLG 14

| | | | | | | | | |

Db 52 PAGPDALGYDKLGP 65

RESULT 14

AM49717
 ID AAM49717 standard; Protein; 720 AA.

XX AC
 XX AC AAM49717;

XX DT
 XX DT 11-JUN-2002 (first entry)

XX Murine calpain protease 12 variant capn12A.

XX Calpain protease; capn12; splice variant; murine; gene therapy;
 KW screening; diagnosis; capn12A.

XX OS
 XX OS Mus sp.

XX PN DE10031932-AL.

XX PD 10-JAN-2002.

XX PF 30-JUN-2000; 2000DE-1031932.

XX PR 30-JUN-2000; 2000DE-1031932.

XX PA (BADI) BASF AG.

XX PI Not given;

XX DR WPI; 2002-115441/16.

XX DR N-PSDB; ABA99768.

XX PT New calpain protein 12 with cysteine protease activity, useful for
 PT treating specific deficiency disorders -

XX PS Claim 2; Page 13-15; 36pp; German.

XX CC This invention describes a novel murine calpain protease 12 (capn12).
 CC The calpain protease of the invention, related proteins and nucleic acid
 CC that encodes it, are useful for treatment (including gene therapy) of
 CC diseases associated with insufficient expression of the calpain protease.
 CC The protein is also used to screen for calpain protein effectors and to
 CC raise specific immunoglobulins (Ig) useful for diagnosis. Also the
 CC polynucleotide encoding capn12 is useful, e.g. as primers and probes, for
 CC diagnosis of diseases, or predisposition to them, and for recombinant
 CC production of capn12. This sequence represents the calpain protease
 CC splice variant capn12A described in the disclosure of the invention.

XX SQ Sequence 720 AA;

Query Match 50.5%; Score 50; DB 23; Length 720;
 Best Local Similarity 64.3%; Pred. No. 44;
 Matches 9; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 PEWPSYLGVEKLG 14

| | | | | | | | | |

Db 52 PAGPDALGYDKLGP 65

RESULT 15

ABP10799

ID ABP10799 standard; Protein; 82 AA.

XX AC
 XX AC ABP10799;

XX DT 24-JUN-2002 (first entry)

XX Human OREX protein sequence SEQ ID NO:21580.

XX Human; open reading frame; OREX; gene therapy; cancer; cirrhosis;
 KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
 KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
 KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;

KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN WO200192523-A2.
XX
PD 06-DEC-2001.
XX
PF 29-MAY-2001; 2001WO-US10836.
XX
PR 30-MAY-2000; 2000US-206132P.
PR 29-AUG-2000; 2000US-228716P.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Shimkets RA, Leach MD;
XX
XX WPI; 2002-106308/14.
DR N-PSDB; ABN26551.
XX
XX Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders
XX
PS Disclosure; SEQ ID 21580; 1037pp; English.
XX
CC The present invention describes substantially purified human proteins
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC in the specification). ABN15762 to ABN27252 encode the human ORFX
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC treating or preventing a pathology associated with an ORFX-associated
CC disorder in humans, and in the manufacture of a medicament for treating a
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC sequences can be used in gene therapy. ORFX sequences can be used in the
CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC osteoarthritis, neurodegenerative disorders, disorders related to organ
CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC storage disease, various immune deficiencies and disorders, infectious
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC bone degenerative disorders, or periodontal disease, and for gut
CC protection or regeneration and treatment of lung or liver fibrosis,
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 82 AA;
XX
XX Query Match 49.0%; Score 48.5; DB 23; Length 82;
XX Best Local Similarity 60.0%; Pred. No. 7.1;
XX Matches 9; Conservative 3; Mismatches 2; Indels 1; Gaps 1;
XX
XX 1 PEPESYLG-YEXLGP 14
XX 1 |||:||| :|| ||
XX 32 PWPSPHIGNHKKRGP 46
XX
XX Search completed: October 2, 2003, 14:33:40
XX Job time : 83 secs